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Abstract
Sprowles, Jenna Leigh Nelms. Ph.D. The University of Memphis. December
2014. The Effects of Diethylstilbestrol Administration During Late Pregnancy on
Anxiety- and Depressive-related Behaviors in C57Bl/6 Mice. Major Professor: Helen J.
K. Sable, Ph.D.
Exposure to the potent synthetic estrogenic compound diethylstilbestrol (DES)
during early development has been found to elicit numerous detrimental effects.
Prescribed to millions of pregnant women from the 1930s to the 1970s, it has been shown
that exposure to DES caused significant reproductive organ abnormalities and
dysfunction in both men and women (DES sons and daughters, respectively) who were
exposed in utero. A high incidence of psychiatric disorders has also been reported,
primarily in adult DES daughters. Because of estrogen’s well-known influence on
emotion, it has been suggested that exposure to this estrogenic compound may be able to
disturb the normal regulation of behaviors modulated by estrogen and estrogen receptors
(i.e., emotion-related behaviors). The current study investigated the effects of gestational
DES exposure on anxiety- and depressive-related behaviors during adulthood in female
mice. Pregnant C57Bl/6 mice were exposed to either vehicle or one of three doses of
DES (.1, 1.0, or 10.0 µg/kg/day) from gestational day 11 to 17 via oral gavage. Because
there have been no published reports examining the possible effects of DES exposure
during pregnancy on the enhancement of postpartum depression and anxiety, associated
behaviors in the dams were also assessed. Following parturition, all dams were
ovariectomized. Three female offspring were retained from each litter at weaning. When
the offspring reached adulthood, one female was ovariectomized, one had a sham
surgery, and one served as the intact control. Two weeks after surgery (or at a similar age
in the intact mice), anxiety- and depression-like behaviors were assessed using the
vi

Elevated Zero Maze, Open Field, Tail Suspension, and Forced Swim Tests. Overall, the
results for this study revealed that exposure to DES during late pregnancy did not
provoke a significant influence over anxiety- and depressive-like behaviors in dams or
female offspring.
Keywords: behavioral toxicology, estrogenic endocrine disrupter, mood disorders
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Chapter 1: Introduction
Defining Endocrine Disrupting Chemicals
Endocrine disrupting chemicals (EDCs) are compounds that have the ability to
either mimic or block the normal effects of hormones at the target receptor or tissue;
EDCs can also exert their effects by stimulating or inhibiting production of endogenous
endocrine system hormones (U.S. Environmental Protection Agency [U.S. EPA], 2011).
EDCs can be either synthetic or natural and are able to produce a wide range of adverse
effects on both behavior and physiology (Patisaul & Adewale, 2009; Schug, Janesick,
Blumberg, & Heindel, 2011). As such, EDCs alter functions that hormones normally
control.
Critical to any EDCs’ ability to elicit harmful effects is the timing of exposure.
During the sensitive window of perinatal development, fetuses and neonates are
especially vulnerable to environmental insult (Gore, 2010; Patisaul & Jefferson, 2010;
Schonfelder, Friedrich, Paul, & Chahoud, 2004). Specifically, during perinatal
development, normal endogenous estrogens and androgens organize the brain and
reproductive system in a sexually dimorphic way. This organization causes both
structural and functional distinctions between males and females that in some cases do
not become apparent until later in life (Gore, 2008; Gorski, 1985; Palanza, Gioiosa, vom
Saal, & Parmigiani, 2008; Schwarz & McCarthy, 2008). When exogenous chemicals like
EDCs are introduced to the developing organism, profound and long-term adverse
outcomes are probable (Gore, 2008). The “Fetal Basis of Adult Disease” (or FEBAD)
hypothesis is especially pertinent to neuroendocrine systems (Gore, Heindel, & Zoeller,
2006; Heindel & Levin, 2005; Patisaul & Adewale, 2009).
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To further highlight the importance of critical periods of development, it has been
discovered that exposure to EDCs early in pregnancy can induce different effects
compared to exposure later in pregnancy or exposure during early childhood (Heindel,
2007; Schug et al., 2011). Therefore, exposure to EDCs can have not just tissue-specific
effects, but also time-specific outcomes. It is also important to keep in mind that exposure
to any given EDC can occur either alone or concurrently with other EDCs or
environmental stressors, implying that disease etiology may be due to additive or
synergistic chemical affronts at any point during these critical periods of development
(Heindel & Newbold, 2009).
Overview of Diethylstilbestrol
Diethylstilbestrol, or DES, is a diphenyl compound with numerous toxic effects as
well as robust estrogenic properties. It has been shown that when administered orally,
DES is five times more potent than estradiol (Korach, Metzler, & McLachlan, 1978;
Marselos & Tomatis, 1993). DES is also a well-known EDC that has a notorious history.
From 1938 to 1971, this potent synthetic estrogen was prescribed to approximately 4 to 6
million pregnant women in the United States (and between 2 and 10 million women
worldwide) to prevent miscarriage and promote healthy babies (Patisaul & Adewale,
2009; Reed & Fenton, 2013). Specifically, it was thought that DES would reduce the risk
of spontaneous abortion or preterm birth by maintaining placental steroid production
(Marselos & Tomatis, 1992). Even after a 1953 report about how DES was not successful
in this regard (Dieckmann, Davis, Ryjenkiewicz, & Pottinger, 1953), there was an
increase in DES prescriptions for clinical use (Marselos & Tomatis, 1992).

2

However, instead of protecting the developing offspring, DES-exposed children
(both males and females) experienced adverse reproductive effects (Patisaul & Adewale,
2009). Vaginal adenocarcinoma, a rare type of cancer, was detected in many women
whose mothers were given DES during pregnancy - a group now referred to as “DES
daughters” (Herbst, Green, & Ulfelder, 1970; Herbst, Ulfelder, & Poskanzer, 1971).
Following the discovery in 1971 that DES was a causal agent in the development of this
disease, the U.S. FDA prohibited the use of DES for pregnancy care (Couse et al., 2001;
Herbst, 2000). Not only do DES daughters have an extremely elevated chance of
developing this form of cancer, they also experience reduced fertility, increased risk of
infertility, more difficult and failed pregnancies (Goldberg & Falcone, 1999; Palmlund,
1996; Schug et al., 2011), abnormal anatomy and function of the oviduct and cervix, and
a T-shaped uterus (Diamanti-Kandarakis et al., 2009; Jefferies et al., 1984). Some of
these outcomes are thought to occur via binding to ERα and subsequent signaling
cascades resulting in irregular control of Hox genes (Block, Kardana, Igarashi, & Taylor,
2000; Couse et al., 2001), which are involved in overseeing the appropriate spatial
development of the reproductive tract (Block et al., 2000).
DES sons have also suffered the effects of prenatal exposure to this EDC. They
exhibit increased incidences of urogenital malformations, undescended testes, testicular
cancer, and lower sperm mobility and density (Diamanti-Kandarakis et al., 2009; Patisaul
& Adewale, 2009); such abnormalities are possibly caused by an up-regulation of ERα
expression in the epididymis (Atanassova et al., 2001). These effects have also been
observed in animal models (Maranghi, Tassinari, Moracci, Macri, & Mantovani, 2008),
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further underscoring DES as a causative agent in these disorders (Diamanti-Kandarakis et
al., 2009).
Experimental studies employing the use of rodents have demonstrated that
developmental exposure to DES was the main factor causing the aforementioned
reproductive malformations. For example, one study using ER knockouts found that
ERαKO mice exposed to DES from GD 1 to 5 did not display the detrimental
reproductive tissue phenotypes that wild-types exhibited, suggesting that DES elicits
many of its effects via binding to ERα (Couse et al., 2001). However, the more specific
and detailed mechanisms are not as well characterized (Marselos & Tomatis, 1992;
1993). It is accepted, though, that abnormal estrogen signaling during development is
quite harmful. Further, the atypical estrogen signaling resulting from DES administration
is thought to disturb the normal regulation and expression of estrogen-regulated genes
and eventually the differentiation and proliferation of certain cell populations (Couse et
al., 2001).
Timing of DES exposure has also been shown to play a role in the effects in DES
children. There are considerable disparities in the incidence and degree of the disorders
associated with DES exposure in utero depending upon timing of first exposure, the total
dose given, and the duration of exposure (Robboy et al., 1981, 1984). This further
illuminates the significance of critical periods and increased susceptibility to EDCs
during perinatal development.
Problems with reproduction and reproductive organs are not the only struggles
associated with in utero exposure to DES. DES daughters have also reported higher rates
of depression and mental health issues (O’Reilly, Mirzaei, Forman, & Ascherio, 2010;
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Vessey, Fairweather, Norman-Smith, & Buckley, 1983). In animal models,
developmental DES exposure has been reported to cause altered socio-sexual as well as
nonsocial behaviors in males and females (Tomihara et al., 2006). Therefore, this
estrogenic chemical also has the ability to modify behavioral outcomes.
Importance of Estrogen
When having a discussion regarding the effects of exposure to EDCs like DES on
the brain and behavior, it is also necessary to understand the neurobiological and
behavioral influence of estrogen (E2; 17β-estradiol) during early development and during
adulthood. Because DES is a potent estrogen agonist, normal downstream signaling
results can be altered when DES binds to estrogen receptors (ERs) (Couse et al., 2001).
Thus, knowledge of E2’s powerful effects on numerous processes can aid in ascertaining
a more thorough knowledge about the specific mechanisms and consequences of DES
exposure.
Enzymatically produced by cholesterol modification, the estrogens are a group of
steroid hormones that play a critical role in numerous processes of early development. In
the final step of E2 synthesis, the p450 enzyme aromatase, also termed estradiol synthase,
aromatizes the A ring of testosterone, thereby generating estradiol (McCarthy, 2008;
Schug et al., 2011). E2 is often denoted as a gonadal steroid because of its synthesis in
both the adult ovaries and the brains of neonatal males from androgens originating in the
developing testes. In addition to this classification, E2 could also be categorized as a
neurosteroid because all the required enzymes to generate this compound have been
found in the brain, and some research has shown that it can possibly be synthesized de
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novo from cholesterol in the brain – specifically in the hippocampus and cortex
(Amateau, Alt, Stamps, & McCarthy, 2004; McCarthy, 2009).
The results produced by developmental E2 activity are largely enduring and vary
extensively. For example, developmental E2 activity is responsible for instituting
regional sex differences (sexually dimorphic regions) as well as for influencing both
neurodamaging and neuroprotective effects in the brain. E2 is involved in apoptosis,
synaptogenesis, and the physical aspects of astrocytes and neurons (e.g., dendritic
branching). Thus, substantial interest exists regarding how estrogenic EDCs interfere
with these normal E2 functions (McCarthy, 2008).
The sexually dimorphic brain. Endogenous steroid hormones, especially E2, are
vital in the proper sexually dimorphic organization of the brain (Frye et al., 2012; Gore,
2010). Based on the specific brain region and activity being regulated, sex-based
differences in the brain are prevalent and vary in power and consequence, with the most
consistent and profound being related to reproduction. Other sex differences like those
related to stress, anxiety, locomotion, and cognition are not as robust but are still
recognized and authentic (McCarthy, 2008).
Known as the organizational/activational hypothesis of brain sex differentiation,
steroidal compounds are active during the perinatal sensitive period and determine the
structure of certain sexually dimorphic brain regions as male or female. Consequently,
these areas are able to influence sexual behavior in adulthood if the appropriate hormone
exposure occurs later in life (McCarthy, 2008). Another important notion in research
regarding development of brain sexual dimorphism is the aromatization hypothesis of
brain sex differentiation. This theory holds that fetal alpha-fetoprotein (AFP) sequesters
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maternal E2, and testosterone derived from the testes diffuses to the male brain where
aromatase converts it to E2. Due to the presence of E2, the course of actions in which
masculinization of the male brain occurs is then activated. If no E2 reaches the
developing brain, feminized brain structures will result (i.e., the female morphology is
considered the default version) (Adewale, Todd, Mickens, & Patisaul, 2011; McCarthy,
2008). Consequently, early exposure to estrogen-mimicking EDCs like DES, that do not
bind to AFP, could masculinize the female brain (Adewale et al., 2011), resulting in
altered brain morphology and behavior.
Chemicals such as DES with the ability to mimic E2 (and also surpass AFP’s
protective binding) have obvious potential to disrupt ER expression in numerous areas,
especially those involved in sexually dimorphic reproductive behavior and physiology.
Of course it is incredibly important to keep the idea of a critical period of vulnerability in
mind. It is during this sensitive time that irreversible changes can be elicited. Such a
concept is undeniably tied to the FEBAD (Fetal Basis of Adult Disease) hypothesis - fetal
(and neonatal) exposure to estrogenic endocrine-disrupting chemicals is able to
negatively impact adult health (Patisaul & Adewale, 2009).
In general, E2’s diverse roles in both the developing and mature brain are farreaching. Its influence on various and inter-related aspects of the brain include
organization of neuronal cells, regulation of numerous signaling pathways, and proper
differentiation of vital sexually dimorphic regions. It is in this latter function that leads to
a discussion regarding E2’s effects on emotion-related characteristics – of both animals
and humans. Anxiety- and depressive-like behaviors are normally divergent in males and
females. Therefore, disruption of typically dimorphic areas of the brain by estrogenic
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EDCs such as DES may alter such behavior and contribute to elimination or reversal of
such sex differences.
E2 and specific functions of ERs. As previously mentioned, EDCs such as DES
disturb processes that hormones normally regulate. The mechanisms of these alterations
are both numerous and complex. Many of these chemicals have the capacity to act
through several pathways (i.e., both DDE [metabolite of the pesticide DDT] and
polychlorinated biphenyls [PCBs] display both estrogenic and anti-androgenic properties)
(Coster & van Larebeke, 2012; Diamanti-Kandarakis et al., 2009).
To gain a more detailed understanding of how estrogenic EDCs induce
downstream changes in numerous processes by binding ERs, it is necessary to investigate
the extensive functions of estrogen and ERs themselves. Normally, upon binding of
estradiol (E2), ERs dimerize and translocate into the nucleus where they bind to estrogen
response elements (EREs), encouraging DNA bending and looping and allowing the
transcriptional machinery to interact with co-regulator proteins. Such proteins include coactivators, co-repressors, co-integrators, transcription factors, and histone
acetyltransferases and deacetylases (Lee, Kim, & Choi, 2012). Depending on the
extracellular proteins and stimuli present, these ER/co-regulator complexes affect the
transcription of specific target genes in certain organs (Zhao, Dahlman-Wright, &
Gustafsson, 2008). This activity presents a precise connection between estrogenic
hormone signals and genetic transcriptional results (Handa, Ogawa, Wang, & Herbison,
2012).
To add to these transcriptional regulatory activities, both ERα and ERβ have also
been found to be involved in rapid, nonclassical estrogen actions in the brain (McEwen &
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Alves, 1999) wherein ERα and ERβ in the plasma membrane and cytoplasm are involved
in modulating the phosphorylation of several kinases and other proteins to regulate
intracellular signaling. Such rapid actions regularly result in the modulation of gene
expression, and vice versa. This relationship between regulation at the genetic level and
regulation at the level of rapid intracellular signaling provides a complex picture of
varied activities for both ERα and ERβ (Handa et al., 2012). When estrogenic EDCs like
DES bind to these ERs, the consequential cellular and genetic activities may be altered.
ERα and ERβ have both coinciding and distinctive distribution throughout various
brain tissues. Both ERs have been found in the preoptic area, bed nucleus of the stria
terminalis (BNST), medial amygdala, and the periaqueductal grey. Concerning ERα, it is
more highly expressed in the ventromedial nucleus (VMN) of the hypothalamus and in
neurons of the arcuate nucleus. Expression of ERβ is more prevalent in the
suprachiasmatic, supraoptic, and paraventricular hypothalamic nuclei and cerebellum as
well as the dorsal raphe, hippocampus, and cortex (Handa et al., 2012). Not only are these
receptors expressed differently in varied areas of the brain, but they also display
preferential expression in several other tissue types in the body, especially those of the
reproductive organs. It has been found that ERα is predominant in the uterus, prostate
stroma, ovarian theca cells, Leydig cells of the testes, epididymis, and breast tissue, as
well as the liver (Lee et al., 2012). ERβ, however, is more prevalent in the epithelium of
the prostate, testes, ovarian granulosa cells, and bone marrow (Lee et al., 2012). Such
differential expression implies that the activities of these ERs are able to independently
influence several multifaceted functions related to physiology and behavior (Handa et al.,
2012). Studies performed on the brains of adult rodents have found that ERα is more
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involved in regulating reproduction through its activity in the hypothalamus, while ERβ
has a more profound effect over non-reproductive activities (Fan, Xu, Warner, &
Gustafsson, 2010). Therefore, exposure to estrogenic EDCs like DES could lead to
alterations in ER expression and activity, resulting in modifications of the intricate
pathways that control such complex functions.
It is clear that the functions of E2 and ERs are widespread and multifaceted, and
the focus of much of the EDC literature has been on these estrogenic targets. Interactions
of EDCs like DES with ERs could potentially alter these functions, resulting in changes
in both protein expression as well as behavior.
Influence of E2 on Emotion
Neurobiological actions of E2 and effects on anxiety and depression.
Alterations in E2 levels can produce drastic changes in mood and affect, and it is wellknown that estrogens have the ability to affect emotion, especially anxiety (Mora,
Dussaubat, & Diaz-Veliz, 1996; Tomihara et al., 2009). More specifically, E2 has been
shown to interact with serotonergic and GABAergic systems to influence such behaviors
(Krezel, Dupont, Krust, Chambon, & Chapman, 2001; McCarthy, Kaufman, Brooks,
Pfaff, & Schwartz-Giblin, 1995; Mora et al., 1996; Pandaranandaka, Poonyachoti, &
Kalandakanond-Thongsong, 2006). It has been established that during the proestrus phase
of the female estrous cycle, naturally circulating levels of E2 are at their highest, and in
diestrus, E2 is at its lowest level. This higher level of E2 during proestrus is associated
with anxiolytic behavior (Marcondes, Miguel, Milo, & Spadari-Bratfisch, 2001; Mora et
al., 1996). During proestrus, the number of serotonin (5-HT) receptors is significantly
lower than during diestrus (Biegon, Bercovitz, & Samuel, 1980); this reduction in
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receptors is accompanied by a decrease in 5-HT in the hypothalamus as well as in the
limbic and midbrain areas (Kueng, Wirz-Justice, Mensi, & Chappuis-Arndt, 1976). This
collection of data implies that increased serotonergic activity enhances anxiogenic
responses; in particular, the decrease in 5-HT activity during proestrus could account for
lower anxiety levels at this point in the cycle (Marcondes et al., 2001). The potential role
that E2 could be playing in this scenario relates to its influence on 5-HT receptor density.
E2 has been reported to decrease 5-HT1 receptors in the rodent brain (Biegon &
McEwen, 1982). Thus, E2 may be decreasing 5-HT synthesis or receptor density during
proestrus, resulting in anxiolytic behaviors (Marcondes et al., 2001).
Another avenue through which E2 may be affecting anxiety-like behaviors
involves its ability to affect neuronal excitability (Moss & Gu, 1999). Benzodiazepines
and similar anxiolytics act on GABA-A receptors to hyperpolarize the post-synaptic
membrane (Hobbs, Rall, & Verdoon, 1996). It has been reported that progesterone and
E2 together are able to significantly increase the number of GABA receptors in the brains
of ovariectomized rats (Maggi & Perez, 1984). Therefore, higher levels of E2 have been
shown to decrease 5-HT activity, which is associated with anxiolytic behaviors, as well
as modulate GABA receptors that also induce an attenuation of anxiety (Marcondes et al.,
2001).
In addition, the etiology of anxiety and depression disorders has been associated
with the hippocampus, a crucial brain region involved in the regulation of emotional and
cognitive responses and where ERβ is highly expressed. Furthermore, previous research
in both clinical studies as well as animal models has found that E2’s interaction with ERs
influences the development and function of the hippocampus (Fan et al., 2010).
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Numerous studies have shown that ERβ may be playing an important role in the
modulation of anxiety levels (Imwalle, Gustafsson, & Rissman, 2005; Krezel et al., 2001;
Tomihara et al., 2009). Interestingly, Walf and Frye (2007) showed that these anxietyregulating actions of ERβ may be localized to the hippocampus. Rats were microinjected
with an ERβ selective ER modulator (via guide cannulae) into either the hippocampus or
the ventral tegmental area [VTA]. When the hippocampus was the target site (compared
to the VTA control site), rats displayed decreased anxiety behaviors immediately
following microinjection. Also, administration of a selective ERα modulator into both
hippocampus and VTA elicited similar effects as microinjection of the control vehicle
into these sites, suggesting that E2’s anti-anxiety effects likely implicate the actions of
ERβ, specifically in the hippocampus (Walf & Frye, 2007).
Studies utilizing ERβ knockout mouse (KO) models have also shown that this
specific ER may be playing an important role in the modulation of anxiety levels. It has
been reported that female mice (gonadally-intact) with a disrupted ERβ gene exhibited
more anxiety-like behaviors than controls (Krezel et al., 2001). In addition,
ovariectomized ERβ KO mice displayed more anxiety-related behaviors compared to
wild types (Imwalle, Gustafsson, & Rissman, 2005). Such results imply the involvement
of ERβ in the anxiety-reducing effects of E2 (Tomihara et al., 2009).
The amygdala has also been implicated in emotion, especially in the regulation of
fear and anxiety responses (LeDoux, 2000). This limbic region has been shown to be
receptive to treatment with E2. Specifically, administration of E2 was able to increase the
number of synapses on dendritic shafts in neurons of the amygdala (Nishizuka & Arai,
1982). In addition, Rasia-Filho, Fabian, Rigoti, and Achaval (2004) reported that during
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the estrous cycle of rats, when E2 levels are variable, dendritic spine density in the
medial amygdala also changed. Such results imply that the amygdala is responsive to E2
and could potentially be involved in E2’s ability to affect emotion-related behavior (Walf
& Frye, 2006). In rodent models, E2 has been able to alter affective behavior tasks that
engage the amygdala. Using ovariectomized rats, Walf and Frye (2003) found that
subcutaneous injection as well as direct intra-amygdala administration (via guide
cannualae) of E2 augmented stress-induced analgesia after acute exposure to the odor of
a predator. Furthermore, it has been found that when E2 was administered to the medial
amygdala, not other control sites, anxiety-like and depressive-like behaviors similar to
those observed upon systemic dosing of E2 were seen. Specifically, it was reported this
direct E2 administration resulted in attenuated anxiety-like activity (Frye & Walf, 2004a)
in addition to decreased depressive-like behavior in the forced swim test (FST) – a
commonly used measure of depressive behavior (Walf & Frye, 2006). Taken together,
these data indicate that this region is another probable target of E2 with regard to its
influence on emotion-related behavior (Walf & Frye, 2006).
Influence of Developmental Exposure to E2. During fetal life, E2 is a major
factor in the organization of neural circuitry that manages many different neuroendocrine,
cognitive, and behavioral functions (Gore, 2010; Gorski, 1985; Palanza et al., 2008).
Administration of exogenous E2 or ethinyl estradiol (EE2; an estrogenic drug identical to
E2 with an added ethinyl group) to mothers during pregnancy has been found to produce
alterations in offspring in not only reproductive and physiological complications (Ryan &
Vandenbergh, 2006) but also abnormal emotional behaviors (Arabo, Lefebvre, Fermanel,
& Caston, 2005; Dugard, Tremblay-Leveau, Mellier, & Caston, 2001). The exact
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mechanism for this is not known, but prenatal exposure to EE2 has been found to affect
neuronal plasticity (Garcia-Segura, Chowen, Duenas, Torres-Aleman, & Naftolin, 1994)
particularly neurodevelopment in the cerebral cortex (Siddiqui & Shah, 1997), the
hypothalamus (Siddiqui & Shah, 1997), and the amygdala (Siddiqui & Shah, 1997).
Previous research has shown that emotional behaviors have been affected in adult
rodents exposed to exogenous EE2 during early development. In particular, it has been
reported that rats whose dams were administered 15 µg/kg EE2 via intraperitoneal
injections from GD 9 to 14 (a critical time for development of the fetal neural tube and
gross nervous system structures) displayed increased anxiety-like behavior (Arabo et al.,
2005; Dugard et al., 2001), increased depressive-like behaviors (Arabo et al., 2005), and
decreased exploratory behavior (Dugard et al., 2001). Another study investigating the
effects of estrogenic chemicals on behavior found that juvenile rats exposed to 50 µg/L
EE2 during gestation through puberty exhibited a higher level of anxiety and hesitancy to
enter the lit chamber in the Light/Dark box (Patisaul et al., 2012). Ryan and Vandenbergh
(2006) exposed C57Bl/6 mouse dams to 5 µg/kg EE2 via oral gavage from GD 3 to PND
21 and observed that offspring displayed anxiogenic behavior on the Elevated Plus Maze
(EPM) and Light/Dark box. Overall these results suggest that developmental exposure to
EE2 is associated with exhibition of anxiogenic activities and highlights the powerful
effects that estrogen can have over emotion-related behavior.
Adult and peri-menopausal exposure to E2. It has been shown that when E2
levels are disturbed during adulthood, pronounced alterations in mood and affect can be
elicited, and it is recognized that estrogen can modify anxiety levels (Tomihara et al.,
2009). Negative symptoms like depression and anxiety that postmenopausal women
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experience have been correlated with lower levels of estradiol while improved mood has
been elicited by estrogen replacement therapy (Halbreich, 1997). For example, Sherwin
and Gelfand (1985) reported that pre-menopausal women who had undergone total
abdominal hysterectomy (i.e., surgically menopausal) and were treated with either an
estrogen treatment, an androgen treatment, or a combination estrogen-androgen treatment
via intramuscular injections had significantly better depression scores (on the Multiple
Adjective Affective Checklist) compared to a placebo group. Likewise, it was found that
surgically menopausal women who had been administered intramuscular injections of a
combination estrogen-androgen treatment or an estrogen treatment reported more positive
moods than women in the untreated control group (Sherwin, 1988). Whooley, Grady, and
Cauley (2000) also found that postmenopausal women using estrogen replacement
therapy at the time of the study had a significantly decreased risk of reporting six or more
depression symptoms on the Geriatric Depression Scale (GDS) compared to women who
were not taking estrogen. In contrast, Saletu et al. (1995) reported that menopausal
women previously diagnosed with major depression that were given a transdermal
estradiol treatment for 3 months did not significantly differ from those in the placebo
group on the Hamilton Depression Rating Scale.
Numerous studies investigating the effectiveness of treating mood disorders
associated with hormonal changes have been conducted. Depending upon the specific
type of treatment, dosing method, duration of treatment, and type of psychological
assessments used, results have varied. Another possible cause for these inconsistencies
involves activity of estrogen metabolites like estrone (E1) and estriol (E3), which have
not been studied as comprehensively as E2 (Watson, Alyea, Cunningham, & Jeng, 2010).
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However, it is widely accepted that alterations in mood are strongly correlated with
fluctuations in circulating estradiol, and clinical research is ongoing in regards to the best
approach to treat such disorders.
Experimental models using mature rats and mice have also shown that changes in
emotion-related behaviors were associated with a decreased level of circulating estradiol
(Tomihara et al., 2009). For example, Estrada-Camarena, Fernandez-Guasti, and LopezRubalcava (2003) found that administration of E2 and EE2 decreased immobility in the
FST in adult ovariectomized Wistar rats. Likewise, Rachman, Unnerstall, Pfaff, and
Cohen (1998) reported that subcutaneous injections of estradiol benzoate in
ovariectomized Sprague-Dawley rats also induced anti-depressant-like activity in the
FST. Frye and Walf (2004a) reported that ovariectomized Long-Evans rats
subcutaneously injected with E2 and Progesterone (P) made more entries into the center
of the open field and spent more time in the open arms of the EPM compared to the rats
given only E2, P, or vehicle alone. They also found that when E2, P, or E2 + P was
directly injected into the medial amygdala via cannulae, the rats exhibited decreased
anxiety-like behaviors compared to those administered vehicle. Furthermore, Mora et al.
(1996) reported that subcutaneous injections of both P and estradiol benzoate in
ovariectomized Sprague-Dawley rats induced anxiolytic behavior in passive avoidance
conditioning, but estradiol benzoate antagonized P’s anxiolytic effects on the EPM,
suggesting that P and E2 may work together to elicit changes in behavior. Another
example illustrating E2’s anxiolytic influence during adulthood involved behavioral
testing in Wistar rats on the EPM. Marcondes et al. (2001) found that females in
proestrus spent more time in the open arms compared to those in diestrus, when
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circulating E2 is low. In addition, they reported that there was no difference in behavior
when E2 was administered to the rats in diestrus. In contrast, another study that used
adult female Mongolian gerbils reported that chronic oral exposure to EE2 resulted in
increased social investigation but a decrease in time spent in a novel area and frequency
of returns to the home cage in a Free Exploratory Test (Razzoli, Valsecchi, & Palanza,
2005).
Overall, several factors are apparently at play in E2’s effects on emotional
behaviors: dose, dosing duration, and especially the age of exposure (see Table 1 for
details about effects of developmental and adulthood exposure to estrogen on emotion).
When estrogen was administered during development, overwhelmingly negative effects
on anxiety- and depressive-like behaviors in rodents were observed. In contrast, when
given later in life, estrogen has been shown to impact emotion-related behaviors in a
more positive way. This stark difference underscores the vulnerability of the developing
brain and neuroendocrine system and also points to the diverse effects that E2 can
produce.
Postpartum Depression and Anxiety
Pregnancy, parturition, and nursing are able to provoke changes in the mother’s
neuroendocrine system; these changes are induced by the developing placenta’s secretion
of estrogens. When the placenta is lost at birth, a dramatic reduction of estrogens occurs,
and such oscillation in hormone levels in the mother may affect neuronal function and
activity (Byrnes, Casey, & Bridges, 2012). These physiological changes in ovarian
steroids are known to affect behavior and are associated with the onset of postpartum
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Table 1. Estrogenic effects on anxiety- and depressive like behaviors in lab animals and symptoms in human participants

Compound

Estradiol
Benzoate

Behavioral Test

Sex/
Species/
Strain/
OVX’d?

Major Findings

Reference

FST

EB 10 µg/.1 ml vehicle
0 dose control

Adulthood/
7 days/
S.C. injections

Female/
Sprague-Dawley rats
OVX’d

↓ immobility
(compared to 0)

EPM

P (25 mg/kg) or
oil first;
EB (10 µg/kg; 3 hr. later)
or oil
“
“

Adulthood/
1 day/
S.C. injection

Female/
Sprague-Dawley rats
OVX’d

High light condition
Oil + EB; P + EB:
↓ % time open arms
(compared to P + Oil)

Mora et al., 1996

P (25 mg/kg) or
Adulthood/
oil first;
1 day/
EB (10 µg/kg; 3 hr. later) S.C. injection
or oil
“
“

Female/
Sprague-Dawley rats
OVX’d

EB and P:
↓ inhibition of response
(compared to 0)

Mora et al., 1996

Males and Females/
Wistar rats/
F intact

M = F;
Intact F in Pro.:
↑ time in open arms
(compared to Di. F);
Intact F in Pro.:
= time in open arms
(compared to Di. F given E2)

Marcondes
et al., 2001

Passive
Avoidance

E2

Dose

Age of Exposure/
Exposure Duration/
Route of Exposure

EPM

EPM

50 µg/kg

E2 (5 µg)
P (500 µg)
E2 + P
0 dose control

Adulthood/
1 day/
I.P. injection

Adulthood/
2 days/
S.C. injections

Female/
Long-Evans rats
OVX’d

E2 + P group:
↑ time open arms
(compared to E2, P, 0)

Rachman et al. 1998

Frye & Walf, 2004

(table continues)
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Table 1. Estrogenic effects on anxiety- and depressive like behaviors in lab animals and symptoms in human participants

Compound

Behavioral Test

EPM

EE2

Dose

E2 (5 µg)
P (500 µg)
E2 + P
0 dose control

Age of Exposure/
Exposure Duration/
Route of Exposure

Sex/
Species/
Strain/
OVX’d?

Major Findings

Reference

Adulthood/
2 days/
Cannuala to
amygdala

Female/
Long-Evans rats
OVX’d

E2 + P. E2, P:
Frye & Walf, 2004
↑ time open arms
↑ entries into open arms
(compared to 0)

OFT

E2 (5 µg)
P (500 µg)
E2 + P
0 dose control

Adulthood/
2 days/
S.C. injections

Female/
Long-Evans rats
OVX’d

E2 + P group:
↑ entries into center
(compared to E2, P, 0)

Frye & Walf, 2004

OFT

E2 (5 µg)
P (500 µg)
E2 + P
0 dose control

Adulthood/
2 days/
Cannuala to
amygdala

Female/
Long-Evans rats
OVX’d

E2 + P. E2, P:
↑ entries into center
(compared to controls)

Frye & Walf, 2004

FST

E2 (2.5-10 µg/rat)
0 dose control

Adulthood/
1 inj. in 2 days/
S.C. injections

Female/
Wistar rats/
OVX’d

↓ immobility
(compared to 0)

EstradaCamarena

et al., 2003

EPM

EE2 (5 µg/kg/day)
0 dose control

GD 3- PND 21/
Oral gavage to dams/
Behav. Testing PND 42

Female/
C57-Bl6 Mice/
OVX’d

↓ time open arms
(compared to 0)

EPM

EE2 (15 µg/kg/day)
0 dose control

GD 9-14/
I.P. injections to dams/
Behav. Testing at
2.5-3 months of age

Males and Females/
DA/Han rats/
Intact

↑ time closed arms
(compared to 0)

Ryan &
Vandenbergh, 2006
Dugard et al.,2001

(table continues)
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Table 1. Estrogenic effects on anxiety- and depressive like behaviors in lab animals and symptoms in human participants

Compound

Behavioral Test

EPM

Dose

Age of Exposure/
Exposure Duration/
Route of Exposure

Sex/
Species/
Strain/
OVX’d?

Major Findings

Reference

↑ time closed arms
↓ open arm entries
(compared to 0)

EE2 (15 µg/kg/day)
0 dose control

GD 9-14/
I.P. injections to dams/
Behav. Testing at
2.5-3 months of age

Males and Females/
DA/Han rats/
Intact

Free Exploration Test

EE2 (15 µg/kg/day)
0 dose control

GD 9-14/
I.P. injections to dams/
Behav. Testing at
2.5-3 months of age

Males and Females/
DA/Han rats/
Intact

↑ latency to enter novel Arabo et al., 2005
chamber
↓ time in novel novel
chamber
↓ entries into novel chamber
(compared to 0)

Free Exploration Test

EE2 (.04 µg/kg/day)
0 dose control

Adulthood/
3 weeks/
Oral exposure

Females/
Mongolian gerbils/
Intact

↓ time in novel novel
chamber
↓ transitions to home-cage
(compared to 0)

Light/Dark Chamber

EE2 (5 µg/kg/day)
0 dose control

GD 3- PND 21/
Oral gavage to dams/
Behav. Testing PND 42

Light/Dark Chamber

EE2 (1.1 µg/kg/day)
during gestation;
(1.4 µg/kg/day)
during lactation;
(around 1.0 µg/kg/day)
post-weaning

GD 6 – PND 40/
Males and Females/
Dissolved in drinking
Wistar rats/
water/
Intact
Behav. Testing between
PND 24-28

Female/
C57-Bl6 Mice/
OVX’d

Arabo et al., 2005

Razzoli
et al., 2005

↓ time in lighted area
(compared to 0)

Ryan &
Vandenbergh, 2006

↓ % rats to enter
light chamber
(compared to 0)

Patisaul et al.,
2012

(table continues)
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Table 1. Estrogenic effects on anxiety- and depressive like behaviors in lab animals and symptoms in human participants

Compound

Behavioral Test

Major Findings

Reference

EE2 (15 µg/kg/day)
0 dose control

GD 9-14/
I.P. injections to dams/
Behav. Testing at
2.5-3 months of age

Males and Females/
DA/Han rats/
Intact

↓ hole pokes
(compared to 0)

Dugard et al., 2001

FST

EE2 (15 µg/kg/day)
0 dose control

GD 9-14/
I.P. injections to dams/
Behav. Testing at
2.5-3 months of age

Males and Females/
DA/Han rats/
Intact

↑ immobility
(compared to 0)

Arabo et al., 2005

FST

E2 (2.5-10 µg/rat)
0 dose control

Adulthood/
1 inj. in 2 days/
S.C. injections

MAACL

Climacteron
(Estrogen-Androgen);
Delestrogen
(Estrogen);
Delatestryl
(Androgen)
Placebo

Adulthood/
3 months on;
1 month off;
3 months on
different
treatment/
I.M. injections

Oophorectimized
women;
Control: women with
hysterectomy but
intact ovaries

MAACL

Climacteron
(Estrogen-Androgen);
Delestrogen
(Estrogen);
Placebo

Adulthood/
1 inj./
I.M. injection

Oophorectimized
women;
Control: women with
hysterectomy but
intact ovaries

Hole-board

HRT

Dose

Sex/
Species/
Strain/
OVX’d?

Age of Exposure/
Exposure Duration/
Route of Exposure

Female/
Wistar rats/
OVX’d

↓ immobility
(compared to 0)

EstradaCamarena
et al., 2003

↓ depression scores
(all compared to 0)

Sherwin &
Gelfand, 1985

E-A and E groups:
↓ depression scores
(compared to 0);
No anxiety effects

Sherwin, 1988

(table continues)
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Table 1. Estrogenic effects on anxiety- and depressive like behaviors in lab animals and symptoms in human participants

Compound

Behavioral Test

Dose

DMRS

Climacteron
(Estrogen-Androgen);
Delestrogen
(Estrogen);
Placebo

HAMD;
KI

Estraderm TTS
(50 µg patch)
Placebo

GDS

Estrogen therapy

Age of Exposure/
Exposure Duration/
Route of Exposure

Adulthood/
1 inj./
I.M. injection

Adulthood/
2 x’s weekly for
3 months/
Transdermal patch
Adulthood/
Oral or transdermal

Sex/
Species/
Strain/
OVX’d?

Oophorectimized
women;
Control: women with
hysterectomy but
intact ovaries

Menopausal women
diagnosed with
major depression

Menopausal women
classified as either:
Current therapy user
Past therapy user
Never therapy user

Major Findings

Reference

E-A group:
↓ dysphoric mood
(compared to E, 0);
E group:
↓ dysphoric mood
(compared to 0)

Sherwin, 1988

= scores
(compared to 0)

Saletu et al., 1995

Current E2 users:
↓ risk of reporting
6+ depression
symptoms
(compared to past
or never users)

Whooley
et al., 2000

Notes. OFT = Open Field Test, EPM = Elevated Plus Maze, FST = Forced Swim Test, HRT = Hormone Replacement Therapy, MAACL = Multiple Adjective
Affect Checklist, DMRS = Daily Menopausal Rating Scale, HAMD = Hamilton Depression Rating Scale, KI = Kupperman Index, GDS = Geriatric Depression
Scale, EB = Estradiol Benzoate, E2 = 17β-estradiol, EE2 = Ethinyl Estradiol, P = Progesterone, OVX’d = Ovariectomized, M = Male, F = Female, ↓ decreased, ↑
increased, = equal to
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depression (Watson et al., 2010). More specifically, steroid hormones are able to cross
the blood-brain barrier to directly alter cellular activity and function as well as influence
neurotransmitter systems that modulate anxiety and depression, thus affecting postpartum
mood (Lonstein, 2007).
The underlying mechanism for the development of postpartum depression (PPD)
is not fully understood. In the final trimester of pregnancy for humans, it is typical to
have high levels of estrogen and progesterone as well as a hyperactive hypothalamicpituitary-adrenal (HPA) axis leading to elevated plasma cortisol that is also promoted by
high levels of estrogen and progesterone (Bloch, Daly, & Rubinow, 2003; Nolten,
Lindheimer, Rueckert, Oparil, & Ehrlich, 1980; Tarantino, Sullivan, & Meltzer-Brody,
2011). At childbirth and in the beginning of the postpartum period, there is not only a
steep drop in estrogen and progesterone levels but there is also diminished HPA activity
because of repressed secretion of hypothalamic corticotrophin-releasing hormone
(Magiakou et al., 1996). It is known that estrogen and progesterone are able to greatly
influence the HPA axis and may possibly prompt aberrations in that area in women
predisposed to anxiety or depression (Tarantino et al., 2011). Furthermore, Bloch et al.
(2003) has been shown that depressive symptoms were engendered following
pharmacological withdrawal from E2 and progesterone in women who had previously
suffered from PPD. It has also been reported that treatment with E2 during the
postpartum period in women with PPD has resulted in a decrease of depressive symptoms
(Ahokas, Kaukoranta, & Aito, 1999; Ahokas, Kaukoranta, Wahlbeck, & Aito, 2001).
To examine potential mechanisms for PPD, experimental studies utilizing animal
models have used a hormone-simulated pregnancy (HSP) regimen (Navarre, Laggart, &
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Craft, 2010). In this HSP model, daily hormone injections are administered to simulate
the hormone levels achieved during pregnancy. Following termination of the injections,
the female rodents are tested for depressive-like behaviors, typically on the Forced Swim
Test. These studies have shown that the withdrawal of E2 following HSP led to increased
immobility in this test (i.e., more depression-like behavior) compared to control animals
(Galea, Wide, & Barr, 2001; Stoffel & Craft, 2004). In addition, Molina-Hernandez and
Tellez-Alcantara (2001) have reported that rats (previously pregnant and still gonadally
intact) displayed more depressive-like behavior in the Forced Swim Test during the early
postpartum period compared to rats in mid-pregnancy. Such results suggest that E2
withdrawal is most likely one of the primary factors in the etiology of PPD. One
proposed reason for this association between the reduction in E2 and depressive
symptoms implicates the disturbance of serotonergic and/or noradrenergic
neurotransmission. As stated previously, it is known that E2 is able to downregulate
certain 5-HT receptors, and it has also been found to upregulate tryptophan hydroxylase,
the enzyme necessary for the conversion of tryptophan into 5-HT (Navarre et al., 2010;
Pecins-Thompson, Brown, Kohama, & Bethea, 1996; Rubinow, Schmidt, & Roca, 1998).
Therefore, it seems possible that exposure to an EDC like DES during pregnancy could
influence E2’s normal postpartum effects in the brain and result in an exacerbation of any
abnormalities that might occur following childbirth.
Concerning postpartum anxiety, there are several hypotheses speculating its
etiology. Most women actually experience a reduction in anxiety after childbirth, and
parturient rodents typically exhibit anxiolytic behaviors (Lonstein, 2007). However, PPD
is commonly associated with peripartum anxiety in women (Barnett & Parker, 1986), and
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this type of anxiety is a strong predictor of PPD (Bergant, Heim, Ulmer, & Illmensee,
1999). One theory regarding the precipitation of postpartum anxiety involves abnormal
fluctuation of prolactin (PRL) and oxytocin (OT) during the peripartum period, and
higher levels of these hormones are associated with reduced anxiety (Lonstein, 2007). It
is thought that abnormal activity of hypothalamic PRL- and OT-synthesizing neurons
projecting to numerous brain areas may be potentially involved in the regulation of
anxiety following childbirth (Lonstein, 2007; Paut-Pagano, Roky, Valatx, Kitahama, &
Jouvet, 1993; Sofroniew, 1980). In addition, one factor that has received much attention
regarding its possible role in affecting postpartum anxiety is activity of the HPA axis. As
previously stated, the HPA axis is suppressed during late pregnancy (de Weerth &
Buitelaar, 2005). It is thought that the lack of continued suppression during the
postpartum period may result in hyperarousal and anxiety (Lonstein, 2007; Tsigos &
Chrousos, 2002). Even more hyperarousal may be elicited because of a reduction in the
usual anxiolytic effects of ovarian steroids, which could be due to such high HPA
activation (Walf & Frye, 2005).
Estrogens, progestins, and other neurosteriods are known to radically oscillate
during the peripartum period. These hormones enter the brain and may affect postpartum
mood indirectly by altering activity of serotonergic, dopaminergic, and GABAergic
neurotransmitter systems that can modulate anxiety (Andrade, Nakamuta, Avanzi &
Graeff, 2005; Birzniece et al., 2006; Pandaranandaka et al., 2006). However, there is not
much support for the hypothesis that ovarian hormones play a significant role in the
production of persistent postpartum anxiety (Lonstein, 2007). It has been shown, though,
that plasma, hippocampal, and cortical levels of alloprenanolone, a reduced metabolite of

25

progesterone that also acts as a positive allosteric regulator of the GABA-A receptor, falls
significantly within 3 days following parturition in rats (Concas, Follesa, Barbaccia,
Purdy, & Biggio, 1999; Frye & Walf, 2004b). Furthermore, in women, alloprenanolone
levels also stay quite low for at least 6 months after childbirth (Epperson et al., 2006).
Perhaps this abrupt reduction in neurosteroids and resulting inactivity in the activation of
the GABA-A receptor could produce an upsurge in neural excitability and anxiety
(Lonstein, 2007).
Reported Effects of DES on Emotion
Due to the influence on emotion-based behaviors that alterations in E2 and/or ERs
can elicit, it is clear that estrogenic EDCs could potentially change the downstream
signaling cascades that are responsible for producing the numerous gene and protein
products affecting hormone levels and brain morphology that eventually contribute to the
final endpoint – altered behavior. Recall that DES was administered to pregnant women
beginning in the 1930s and into the early 1970s to prevent miscarriage and pregnancyrelated difficulties. It has been speculated that this estrogenic compound may also be able
to influence the brain, behavior, and resulting psychological conditions (Vessey et al.,
1983). As with other estrogenic endocrine disruptors, DES does not bind to AFP, thus
allowing it to reach the fetal brain to induce changes in E2 and ER-regulated activities
that are able to affect anxiety- and depressive-like behavior in humans and animals. It has
been reported that DES-exposed women have an amplified proportion of depression,
anorexia, and learning disabilities (O’Reilly et al., 2010; Vessey et al., 1983).
An extensive literature search resulted in several studies examining the
prospective link between developmental exposure to DES and depression symptoms. The
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main focus of most of these papers is concerning psychiatric illness in adult women that
were subjected to DES in utero. However, some studies do describe psychological
effects, or the absence thereof, in exposed men as well.
Early developmental exposure. Numerous epidemiological investigations have
examined the incidence of psychological disorders with a primary emphasis on the
occurrence of major depressive disorder (MDD) in adult men and women exposed to
DES in utero. Contradictory results have been reported. Because of the nature of the
studies (varied questionnaires and criteria used for diagnosis, sample sizes, methods of
collecting data), interpretation is difficult (Kebir & Krebs, 2012). Vessey et al. (1983)
was the first to report higher rates of depression and anxiety disorders in DES sons and
daughters. However, in the Vessey study, a questionnaire was sent in the mail to general
practitioners of the participants and the results were not centered on standardized criteria
for diagnoses and were not based on structured interviews with patients. Several other
studies have utilized small samples (maximum 50 participants in each group) and
evaluated the presence of psychiatric illness by using semi-structured interviews and
standardized criteria (Ehrhardt et al., 1987; Fried-Cassorla, Scholl, Borow, Strassman, &
Bowers, 1987; Meyer-Bahlburg et al., 1985; Pillard et al., 1993). Due to the possible
confound of distress over either actually having or likely developing reproductive
problems, a clinical control group (i.e., women with abnormal Papanicolaou test results)
was included in some studies (Ehrhardt et al., 1987; Fried-Cassorla et al., 1987).
Specifically, Ehrhardt et al. (1987) reported that lifetime rates of MDD were significantly
higher in the DES group compared to general population norms; however, differences
between the DES group and the clinical control Papanicolaou (PAP) group were not
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significant. Two of the small sample studies that did not use a clinical control group
found that DES-exposed men had a significantly higher incidence of MDD during their
lifetimes compared to non-exposed control men (Meyer-Bahlburg et al., 1985; Pillard et
al., 1993).
One study used a large cohort (from the National Cancer Institute) of male and
female participants who had been exposed to DES in utero but only asked women about
issues with mental illness. Titus-Ernstoff et al. (2003) found no differences in the
frequency of depression, anxiety, psychosis, or eating disorders between the DES cohort
and unexposed sisters and age-matched controls. The data was collected through a selfreport questionnaire. Because no standardized criteria or structured interview was
utilized, there is a chance that women suffering from a serious psychiatric illness may not
have participated. This possibility would suggest a potential under-representation of the
real prevalence of psychiatric problems in this cohort (Kebir & Krebs, 2012; TitusErnstoff et al., 2003).
Two more recent studies using large subsamples from general population cohorts
have reported opposing results. Verdoux, Ropers, Costagliola, Clavel-Chapelon, and
Paoletti (2007) surveyed mothers (all participating in a French general population survey)
using self-report questionnaires sent through the mail. The mothers gave information on
psychiatric illness on DES-exposed children as well as unexposed siblings, and results
showed no differences between the groups. In contrast, O’Reilly et al. (2010) used a
cohort from the Nurses’ Health Study II, a group of over 116,000 American female
nurses born between 1946 and 1965 and who have completed a questionnaire about their
lifestyle and any newly diagnosed diseases every two years since 1989. Participants who
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had confirmed exposure to DES completed self-report questionnaires that asked about
history of depression and use of antidepressant medication. It was shown that exposed
women reported a higher incidence of depression (having depression symptoms and use
of antidepressant medication) compared to women who were not exposed.
Only two published papers report results of developmental exposure to DES and
behavioral tests of emotional behavior using animal models. Kubo et al. (2003) found
that DES abolished sex differences observed in control rats in the measure of time spent
in the center of the arena in the OFT. In particular, it was reported that both males and
females in the DES group spent more time in the center, an anxiolytic behavior,
compared to controls. One study investigated the effects of developmental DES exposure
on both wild-type and ERα knockout C57Bl/6J mice. They reported that the mice
prenatally exposed to DES from GD 11 to 17 exhibited anxiety-like behavior in the OFT
as adults, regardless of genotype. However, in the Light-dark transition test, prenatal DES
exposure resulted in elimination of sex differences in the wild-type mice while no DES
effects were observed in either male or female ERαKO mice, suggesting that DES exerts
its influence by binding to ERα (Tomihara et al., 2006).
Kaitsuka et al. (2007) also examined prenatal DES exposure in male mice but
used the passive avoidance test as a measure of learning and memory. They reported that
mice in the DES-exposed group entered the dark chamber (previously associated with
foot shock) significantly more after an acquisition period compared to control animals;
such results suggest a more anxiolytic state and impaired memory in the exposed mice.
Adulthood exposure. Regarding exposure to DES during adulthood in animal
models, there is only one published study that discusses measures of depressive-like
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behavior. Estrada-Camarena et al. (2003) investigated the effects of DES (in addition to
E2 and EE2) administration in adult ovariectomized rats and reported no differences
following DES exposure on behavior in the FST. However, only one subcutaneous
injection of the estrogenic compound was given 48 hours prior to behavioral testing. A
schedule of chronic exposure in an adult animal model would be more informative. There
are no reports of major depression or other psychiatric conditions in the mothers who
were given DES during their pregnancies (see Table 2 for details about effects of
developmental and adulthood exposure to DES on emotion).
Neurobiological mechanisms of DES exposure. The precise mechanisms by
which DES could be eliciting emotion-related behavioral alterations are yet to be
determined. As stated earlier, ERα seems to be the ER subtype most affected by DES.
Furthermore, E2 actions in the hippocampus may also play an important role in
regulating emotion. Prenatal DES exposure in mice has been shown to result in altered
passive avoidance responses in male offspring as well as increases in pCaMKII activity
and expression, a kinase that plays a noteworthy role in promoting long term potentiation
(LTP) in the hippocampus (Kaitsuka et al., 2007; Soeda, Tanaka, Shirasaki, & Takahama,
2010). Interestingly, this altered passive avoidance response and kinase activity was
significantly mitigated in mice prenatally exposed to DES but reared in an enriched
environment (Soeda et al., 2010). Perhaps DES’s ability to disrupt normal hippocampal
signaling activity affecting LTP could similarly influence surrounding signaling
molecules and expression of certain proteins that may also elicit varied outcomes with
regard to regulation of emotion.
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Table 2. Diethylstilbestrol effects on anxiety- and depressive like behaviors in lab animals and symptoms in human participants

Behavioral Test

Dose

Age of Exposure/
Exposure Duration/
Route of Exposure

Sex/
Species/
Strain/
OVX’d?

OFT

6.5 µg/kg/day
0 dose control

GD 0 – PND 21/
Drinking water to dams/
Behav. Testing PND 42

Males and Females/
Wistar rats/
Intact

OFT

0.1 µg/animal
0 dose control

GD 11- 17
Oral exposure to dams/
Behav. Testing PND 35

Males and Females/
C57Bl/6J mice/
some ERαKO;
Some WT

Light/Dark Chamber

0.1 µg/animal
0 dose control

GD 11- 17
Oral exposure to dams/
Behav. Testing PND 35

Males and Females/
C57Bl/6J mice/
some ERαKO;
Some WT

Passive Avoidance
Test

0.1 µg/animal
0 dose control

GD 11- 17
Oral exposure to dams/
Behav. Testing at 11-14 weeks

Males/
DDY mice

Major Findings

Reference

↑ time in center
Kubo et al., 2003
(compared to 0)
DES M = F
(compared to 0 M ≠ F)
↓ time in center
(compared to 0;
regardless of
genotype)

Tomihara et al.,
2006

WT F:
Tomihara et al.,
↓ time in light side
2006
(compared to 0 WT F);
WT M:
↑ time in light side
(compared to 0 WT M);
DES WT M = F:
time in light side
(compared to 0 WT M ≠ F)
↑ entries into lit chamber
(compared to 0)

Kaitsuka
et al., 2007

(table continues)
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Table 2. Diethylstilbestrol effects on anxiety- and depressive like behaviors in lab animals and symptoms in human participants

Behavioral Test

Passive Avoidance
Test

FST

General Practitioner
Questionnaire

SADS-L/RDC

Dose

Age of Exposure/
Exposure Duration/
Route of Exposure

Sex/
Species/
Strain/
OVX’d?

Major Findings

0.1 µg/animal
0 dose control

GD 11- 17
Males/
Oral exposure to dams/
ddyY mice
Behav. Testing at 6 weeks/
Some raised in enriched environ.

.25-1 mg/rat
0 dose control

Adulthood/
1 inj. in 2 days/
S.C. injections

DES tablets
(5 mg/day)
Placebo

Gestation
(starting around
6h week of pregnancy)/
Oral exposure to mothers/
Mean age of exposed
Subjects = 23-29 years

DES exposure
No exposure

Gestation (variable times)/
Women exposed
Mothers given tablets/
in utero compared to
Mean age of exposed
age-matched controls with
Subjects = 25 years
abnormal Pap smears/
Clinic sample

Reference

DES non-enriched:
Soeda
↑ entries into lit chamber
et al., 2010
(compared to DES enriched;
0 enriched)

Females/
Wistar rats/
OVX’d

No significant effects

Male and Female/
Children of women in
University College
Hospital Trial
(randomized,
double-blind controlled
trial of DES for
first pregnancy)
in the 1950s/
Reported by
General Practitioners

↑ incidence of
anxiety and depression
in both sons and daughters
(compared to placebo)

↑ rates of MDD in
both groups;
DES = control

EstradaCamarena et al.,
2003

Vessey et al.,
1983

Ehrhardt et al.,
1987

(table continues)
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Table 2. Diethylstilbestrol effects on anxiety- and depressive like behaviors in lab animals and symptoms in human participants
Age of Exposure/
Exposure Duration/
Route of Exposure

Sex/
Species/
Strain/
OVX’d?

Behavioral Test

Dose

SADS-L/RDC

DES exposure
No exposure

Gestation (variable times)/
Mothers given tablets

SADS-L/RDC

DES exposure
No exposure

Gestation (variable times)/
Mothers given tablets

Men exposed in utero
compared to normal
unexposed men/
Clinic sample

↑ rates of MDD
Meyer-Bahlburg
(compared to controls)
& Ehrhardt,
1985

SADS-L/RDC

DES exposure
No exposure

Gestation (variable times)/
Mothers given tablets

Men exposed in utero
compared to normal
unexposed brothers/
Clinic sample

↑ rates of MDD
Pillard et al.,
(compared to
1993
unexposed brothers);
= rates lifetime depression,
alcoholism, and current
psychiatric symptoms
(compared to
general population)

DIS/DSM III

DES exposure
No exposure

Gestation (variable times)/
Mothers given tablets

Women exposed
in utero compared to
unexposed sisters and
women with abnormal
Pap smears/
Clinic sample

↑ rates of MDD
Fried-Cassorla
(compared to
et al.,
unexposed sisters);
1987
= rates of MDD between
abnormal Pap group
and DES group

Men exposed in utero
compared to men
with minor urological issues
and men possibly exposed/
Clinic sample

Major Findings

↑ rates of MDD in
both groups;
DES = control

Reference

Meyer-Bahlburg
& Ehrhardt,
1987

(table continues)
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Table 2. Diethylstilbestrol effects on anxiety- and depressive like behaviors in lab animals and symptoms in human participants

Age of Exposure/
Exposure Duration/
Route of Exposure

Sex/
Species/
Strain/
OVX’d?

Behavioral Test

Dose

Questionnaire

DES exposure
No exposure

Gestation (variable times)/
Women exposed
Mothers given tablets/
in utero compared to
Most subjects were
unexposed sisters and
older than 35 years
age-matched controls/
combination of 4 DES
cohorts from the
National Cancer Institute

No significant differences
Titusbetween groups
Ernstoff et al.,
2003

Questionnaire

DES exposure
No exposure

Gestation (variable times)/
Women exposed
Mothers given tablets/
in utero compared to
Mean age of subjects
unexposed sisters/
= 36 years
Subgroup of E3N cohort
(general population cohort
of mothers surveyed for
cancer risk factors)

No significant differences
between groups

Verdoux
et al., 2007

Questionnaire

DES exposure
No exposure

Gestation (variable times)/
Mothers given tablets/
Mean age of subjects
= 39 years

↑ history of depression
(compared to controls)

O’Reilly
et al., 2010

Women exposed
in utero compared to
unexposed women/
Subgroup of Nurses’
Health Study II Cohort

Major Findings

Reference

Notes. OFT = Open Field Test, FST = Forced Swim Test, SADS-L/RDC = Schedule for Affective Disorders and Schizophrenia-Lifetime version/Research
diagnostic criteria, DIS/DSM III = Diagnostic Interview Schedule/Diagnostic and Statistical Manual III, DES = Diethylstilbestrol, M = Male, F = Female, ↓
decreased, ↑ increased, = equal to, ≠ no difference
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In addition, Mize, Poisner, and Alper (2001) reported that E2 and DES (when
independently administered) were able to act via ERs to reduce 5-HT(1A) receptor
function in the hippocampus and frontal cortex in an in vitro assay using brain samples
from adult ovariectomized rats. This finding agrees with the results of Marcondes et al.
(2001) and Biegon and McEwen (1982) regarding E2’s ability to reduce 5-HT receptor
expression, dependent upon the level of circulating E2 available. Therefore, DES, like
E2, could modify 5-HT receptor expression in adults to also elicit changes in emotionrelated behaviors.
Rationale and Hypotheses of the Current Study
With the diversity of results in the epidemiological data regarding psychological
health following developmental exposure to DES, there is not a clear consensus regarding
the potential of this estrogenic EDC to be a causative factor in the etiology of anxiety and
depression. A possible and very powerful confound in this research is the knowledge of
exposure and/or problems with reproductive function, and epidemiological research has
not been able to distinctly tease out the specific cause for the higher reported rates of
emotion-related problems in women exposed to DES in utero. The experimental studies
that have used a developmental dosing paradigm have reported similar anxiety-like
behaviors that were observed following exposure to E2 and bisphenol A (BPA), also an
estrogenic endocrine disruptor (Cox, Gatewood, Howeth, & Rissman, 2010; Gioiosa,
Fissore, Ghirardelli, Parmigiani, & Palanza, 2007; Gioiosa, Parmigiani, vom Saal, &
Palanza, 2013; Kubo et al., 2001; 2003; Palanza et al., 2008; Patisaul et al., 2012).
Furthermore, due to estrogen’s ability to influence emotion in adult humans and mature
animals, particularly during and after pregnancy, it is also necessary to assess behavioral
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alterations following DES administration in pregnant adult rodents. It is also known that
there is substantial comorbidity between depression and anxiety disorders (Hirschfeld,
2001). Therefore, the present study intended to investigate the possible emotion-related
behavioral ramifications (measuring both anxiety- and depressive-like behaviors) of
developmental exposure as well as exposure during pregnancy. It was hypothesized that
prenatal DES exposure would result in increased anxiety- and depression-related
behaviors in female offspring. Because the mental health problems have been more
prevalent in DES daughters than DES sons, this project focused on only the female
offspring. In addition, it was predicted that dams exposed to DES would exhibit altered
emotion-related behavior.
Though it has not been prescribed for human use in several decades, investigation
into DES is still quite relevant. Because of its potential to induce transgenerational
genetic modifications that may make it more likely that the children and grandchildren of
the original prenatally exposed generation might develop complications later in life
(Newbold, 2011), more information is needed regarding the effects of this compound on
emotional regulation. Furthermore, due to its similarity to other estrogenic endocrine
disruptors, being able to extrapolate from previous research regarding developmental
exposure and the possible influence it could have on the etiology of psychiatric illness
could be quite telling concerning questions about early exposure to estrogenic EDCs and
their relationship to the FEBAD hypothesis (Kebir & Krebs, 2012).

36

Chapter 2: Methods
Subjects
Eighty female and 40 male C57Bl/6 mice (5-6 weeks of age) were obtained from
Harlan Laboratories and the females were identified by ear punch upon arrival. All mice
were maintained in a temperature- and humidity-controlled room (22 degrees Celsius, 4055% humidity) on a 12:12 hour regular light-dark cycle (on at 0700, off at 1900).
Females were double-housed in a standard polysulfone shoebox cage (inspected and
determined to be free of wear) with wood chip bedding. A standard low soy diet (Harlan
2020X) and reverse osmosis filtered water in glass bottles were available ad libitum.
After one week of acclimation, a breeder male (previously single-housed) was introduced
into the cage with the two females. Starting the following morning, females were checked
daily for the presence of a vaginal plug. If present, the female was moved to her own
cage and that day denoted as gestational day (GD) 0. Females that did not show signs of a
vaginal plug or other signs of pregnancy after seven days were re-paired with a different
breeder male. All procedures were approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of Memphis and were in accordance with the
Public Health Service Policy on Humane Care and Use of Laboratory Animals (National
Institutes of Health [NIH], 2002) and the Guidelines for the Care and Use of Mammals in
Neuroscience and Behavioral Research (National Research Council [NRC], 2003).
Exposure
The female mice were randomly assigned to exposure groups and given one of
four treatments consisting of either DES (0.1, 1.0, or 10.0 µg/kg) (Sigma-Aldrich) or the
control vehicle (tocopherol-stripped corn oil only). Dams were orally gavaged daily
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starting on GD 11 and continuing until GD 17. The appropriate volume of each dose
(typically in the range of 35 - 50 µl, depending on the dam’s weight) was loaded into the
flexible tip of a positive displacement pipette and administered to the dam via oral
gavage. The current study’s planned dosing duration was selected to encompass a critical
time of central nervous system (CNS) development in mice (beginning in late prenatal
life) when estrogen irreversibly organizes brain circuitry in a sex-dependent manner. In
addition, these doses and this timeline were chosen according to other studies that have
examined behavior in prenatally-exposed mice (Kaitsuka et al., 2007; Soeda et al., 2010;
Tomihara et al., 2006). Furthermore, the current study’s proposed doses of DES have
been shown to not elicit any gross physical abnormalities (Fielden, Fong, Haslam, &
Zacharewski, 2002; Fielden et al., 2002), but doses in this range have resulted in altered
behaviors (for examples, see Table 2).
Procedure
Births/weaning and reproductive/developmental endpoints. Three days
following parturition (PND 3), all the pups were sexed, weighed, and examined for any
abnormalities. Any incidence of stillbirth was also recorded. The litters were culled to six
to seven pups (retaining as many females as possible) using cervical dislocation to
euthanize extra pups. In order to increase the size of small litters and to guarantee that
each litter contained at least six to seven pups, extra pups from the same treatment group
were cross-fostered if available. Cross-fostered pups were marked by ear clip and did not
undergo behavioral testing. Successful litters were obtained from 9, 12, 8, and 10 dams
who received the 0, 0.1, 1.0, or 10.0 µg/kg doses, respectively. However, one dam in the
1.0 DES group had only one female. Because preference was given to the OVEX
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condition, this female was ovariectomized but did not survive the surgery, resulting in n
= 7 for female offspring in this exposure group.
Postnatal weight gain was monitored in the pups weekly until weaning on PND
21. Anogenital distance was measured on PND 21 for all pups. On the day of weaning,
each litter’s dam was separated. The dam was re-housed with other dams from the same
treatment group. From each litter, three females were retained for behavioral testing and
were housed in the same cage until surgery. The remaining pups in each litter were
euthanized at weaning via overexposure to CO2, trunk blood collected, and weights of the
brain and liver acquired from one male and one female per litter (when available). Brain
samples were frozen and stored for later analyses.
Ovariectomies. Two days after weaning, dams underwent ovariectomy surgery.
In addition, one-third of the female offspring (on approximately PND 60) also underwent
this surgery. Each mouse was first placed into an induction box containing isofluorane
until adequate anesthesia was obtained at which point they were quickly removed. An
anesthetized animal was placed in lateral recumbency and positioned to breathe into a
nose cone delivering 2-3% isofluorane. Surgery was performed using aseptic methods as
much as possible. Bilateral ovariectomies were performed. The target area was shaved
and betadine antiseptic solution and then 70% alcohol were applied. A .5 cm lateral
incision was made that was about 1 – 1.5 cm caudal to the 13th rib. The fascia was
cleared away using blunt dissection and the underlying muscle wall cut with a scissors.
Forceps were used to locate the fat pad containing an ovary which was extracted through
the incision. A cauterizer was used to remove the ovary. The uterine horn was then
placed back into the body cavity, the muscle wall closed with suture, and the skin
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incision closed with a single stainless steel staple (which was removed 5 to 7 days later).
The same protocol was used for mice that received the SHAM surgery, with the
exception that the ovaries were not removed.
To prevent infection and to reduce pain, subcutaneous injections of baytril and
carprofen (doses based on each animal’s weight) were administered while mice were still
under anesthesia. The anesthesia was then discontinued and mice continuously monitored
until awake and alert enough to move about on forelimbs. Mice were then placed in an
individual cage and observed in the main laboratory until fully awake. Upon regaining
consciousness, each animal was returned to its colony room in the U of M Animal
Vivarium and monitored. Mice were given subcutaneous injections of baytril and
carprofen for two days following surgery. Post-surgical weights were collected daily and
all mice monitored for signs of distress or infection for one week following surgery.
The mice were then given two weeks to recover (also allowing for complete
reduction in circulating estrogen) before undergoing behavioral testing. For each litter,
one female offspring had the ovaries removed (i.e., OVEX female), one female had a
sham surgery wherein the procedure was the same as an ovariectomy with the exception
that the ovaries were not removed (i.e., SHAM female), and the final retained female did
not have surgery (i.e., INTACT female).
Behavioral testing. The dams and all mice retained after weaning underwent all
behavioral tests. The order of testing for all subjects was: Elevated Zero Maze, Open
Field Test, Tail Suspension Test, and Forced Swim Test. There were at least two days
between each testing session.
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Anxiety-related behaviors: Two behavioral tests designed to examine anxietyrelated behaviors in mice were conducted on all retained female offspring. The first
anxiety behavioral test was the Elevated Zero Maze which is one of the most commonly
used behavioral measures of anxiety (Kulkarni, Singh, & Bishnoi, 2007). Anxiogenic
behavior is associated with time spent in the closed quadrants, while anxiolytic behavior
is associated with time spent in the open quadrants. Testing lasted for 5 min. The testing
apparatus consisted of a ZeroMaze Digital Monitoring System (AccuScan Instruments,
Inc., Colombus, OH). The test chamber was a black circular platform and consisted of
open and closed quadrants elevated 108.9 cm off the floor with a platform measuring 5
cm in width. The closed quadrants were enclosed by clear acrylic walls (28.5 cm in
height). The diameter of the maze was approximately 40 cm (inner diameter = 30 cm).
The closed quadrants were equipped with eight light beams that transmitted the amount
of time spent in and activity in the closed quadrants. The open quadrants had a slightly
raised Plexiglas lip to prevent mice from slipping off the maze. Each mouse was placed
in closed Quadrant 1 of the maze to begin the test (see Cook, Williams, & Flaherty,
2001). A thorough cleaning of the maze with ethanol occurred between each subject. The
dependent measures collected included latency to enter an open quadrant, percent time
spent in open and closed quadrants, percent time spent each of the four quadrants, and
activity in closed quadrants.
The next anxiety test for each subject was the Open Field Test (OFT), which has
been used extensively in the literature as a behavioral measure of anxiety (Choleris,
Thomas, Kavaliers, & Prato, 2001). In the OFT, anxiety is quantified based on how
much time the animal spends in the center versus the periphery of the testing chamber.
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Time spent near the periphery is indicative of an anxiogenic state (increased anxiety)
while time in the center of the arena suggests an anxiolytic state (decreased anxiety). The
OFT chamber consisted of a square plastic arena (46.5 x 46.5 x 46.5 cm) bisected with
photobeams and equipped with a video-tracking system. Each mouse was placed in the
center of the arena and allowed to move freely for 10 min. The entire chamber was
placed in a testing cubicle equipped with a fan to buffer extraneous noise. Dependent
measures included time spent in the center area, the number of entries into the center
area, the number of photobeam breaks in the center area, number of photobeam breaks in
the periphery, duration of time spent frozen, number of rears, and duration of rears.
Depression-related behaviors: Two measures of depressive-like behavior were
collected in all of the subjects. The tail suspension test (TST) has been extensively used
to measure depressive-behavior in mice and has the advantage of controlling for
locomotor confounds (Cryan, Mombereau, & Vassout, 2005). For this test, immobility
while suspended is likened to hopelessness and giving up which are significant
characteristics of depression (Cryan et al., 2005). The TST apparatus (Kinder Scientific;
San Diego, CA) consisted of a cubicle furnished with a strain gauge which is a hook
linked to a vertical bar that digitally detected mobility. The mouse was suspended by its
tail with tape from the strain gauge for 6 min. The total duration of immobility was the
dependent measure and was computed as the total time the subject’s movement is below
a pre-determined threshold. Specifically, immobility was characterized as the lack of any
initiated movements and included passive swaying.
The second depressive measure was the forced swim test (FST). The FST
apparatus (Kinder Scientific; San Diego, CA) consisted of a clear Plexiglas or glass
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cylinder (height = 61 cm; diameter = 29 cm) filled with fresh tap water up to the level of
50 cm. The FST protocol used has been previously described (Castagne, Porsolt, &
Moser, 2009; Ferguson, Cisneros, Hanig, & Berry, 2007). Briefly, each mouse was
placed in the water-filled cylinder (temperature ~ 25°C) for 6 min. Afterwards, the
subject was removed, towel dried, allowed to rest in a cage on a heating pad, and then
returned to its home cage. The testing apparatus was emptied, rinsed, and refilled with
fresh water after each subject’s test session to eliminate any pheromone effects. The
duration immobility or floating (making only those movements absolutely necessary to
keep the head above water) was measured. Also, the number of climb/struggle
movements (making lively movements with forepaws, usually against the cylinder wall),
and swim distance (making swimming motions, more than needed to keep the head above
water and usually in a horizontal posture) were recorded.
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Chapter 3: Data Analysis
All statistical analyses were conducted using SPSS for MS Windows (version
22.0, SPSS Inc.; Chicago, IL) with statistical significance set at p < 0.05.
Reproductive/Developmental Endpoints
Dams. Gestational weight gain for the dams was analyzed with a one-way
between subjects ANOVA (DES exposure group was the between-subjects factor).
Offspring. The data analysis for developmental outcomes including postnatal
weight gain and anogenital distance was essentially the same. For these dependent
variables, the mean value for males and females within each litter was calculated and
analyzed with a mixed 4 (DES exposure) x 2 (sex) repeated-measures ANOVA, where
DES exposure was the between-subjects factor, and sex was nested within litter. Because
litters were small and most pups were retained for behavioral testing, there were not
many full sets of male and female littermates sacrificed at weaning. Therefore, for brain:
body weight ratio and liver: body weight ratio, these variables were analyzed with a oneway between-subjects ANOVA separately for males and females.
Behavioral Tests
Dams. The data analysis for each anxiety- and depression-related behavior was
essentially the same. Each dependent variable was analyzed with a one-way between
subjects ANOVA (DES exposure group was the between-subjects factor). Quadrant (for
the EZM) and one-minute block (for the EZM, OFT, TST, and TST) were also included
as repeated-measures factors when appropriate. When significant exposure-related effects
were obtained from the overall analyses, additional Dunnett post hoc analyses were
conducted to determine which exposure groups differed from the control group.
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Female offspring. In instances where fewer than 3 female pups/litter were
available, assignment to the OVEX group was given priority. Missing littermate data was
determined by using the mean for the other females in the same DES exposure and
surgery group. To ensure that this did not dramatically alter the experimental results, any
dependent variable that required mean substitution was analyzed both with the substituted
mean and also by dropping the entire litter from the analysis. In all cases, mean
substitution did not change the overall pattern of results.
The data analysis for each anxiety- and depression-related behavior was
essentially the same. Each dependent variable was analyzed with a 4 (Exposure) x 3
(Surgery) mixed ANOVA. As the three female offspring (OVEX, SHAM, INTACT)
were all from the same dam, this variable was a repeated-measures factor (i.e., nested
within litter). Quadrant (for the EZM) and one-minute block (for the EZM, OFT, TST,
and TST) were also included as repeated-measures factors when appropriate. When
significant exposure or surgery main effects were obtained from the overall analyses,
additional Dunnett or simple contrast post hoc analyses were conducted to determine the
nature of the significant differences.
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Chapter 4: Results
For the sake of brevity, only dependent variables that revealed significant effects
involving exposure for the dams will be discussed. For the female offspring, only
dependent variables that revealed statistical significance for exposure- or surgery-related
effects will be discussed.
Reproductive/Developmental Endpoints
Dams. The effects of DES exposure on gestational weight gain are presented in
Figure 1. There was no significant effect of DES on gestational weight gain in the dams.
Offspring. The effects of DES exposure on postnatal weight gain and anogenital
distance (AGD) are shown in Figures 2 and 3, respectively. The effects of exposure on
brain: body weight (BW) ratio and liver: BW ratio are presented in Table 3. For postnatal
weight gain, there was a significant Exposure x Day [F(9, 102) = 1.988, p = .048] and
Sex x Day [F(3,32) = 4.294, p = 0.12] interaction. There was also a significant main
effect of sex [F(1,34) = 5.940, p = .020] for postnatal weight gain where males weighed
significantly more than females. Further post hoc simple contrasts conducted within each
sex revealed that were no significant exposure-related differences on any day. There were
no exposure-related effects for AGD; however, there was an expected significant effect
of sex [F(1, 34) = 637.156, p < .001] where males had larger AGDs than females (see
Figure 3). Finally, there were no significant effects of exposure found for brain: BW or
liver: BW ratios in male or female offspring.
Behavioral Tests
Dams.
Anxiety measures.
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Table 3. DES Offspring Brain:Body Weight and Liver:Body Weight Ratios
DES Dose
GD 11-17

0 µg/kg/day
MALE (n=4)
FEMALE (n=5)
0.1 µg/kg/day
MALE (n=4)
FEMALE (n=7)
1.0 µg/kg/day
MALE (n=5)
FEMALE (n=2)

Brain:Body Weight (g)

Liver:Body Weight (g)

.039 ± .002
.041 ± .003

.048 ± .003
.046 ± .002

.040 ± .001
.043 ± .001

.045 ± .004
.047 ± .004

.039 ± .001
.043 ± .008

.050 ± .002
.047 ± .008

10.0 µg/kg/day
MALE (n=4)
.039 ± .001
FEMALE (n=1)
.046
Note. Means (± SEM); n = # of weanling samples
DES = Diethylstilbestrol, g = grams
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.048 ± .002
.041

Figure 1. Percent gestational weight gain in dams for all DES exposure groups. The effect of DES exposure was not significant.
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Figure 2. Postnatal weight gain for male offspring (top panel) and female offspring
(bottom panel).
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Figure 3. Anogenital distance (AGD) for male and female DES offspring on PND 21. Males had significantly larger AGDs than
females.
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Elevated zero maze. The effects of DES exposure on the latency to enter the open
quadrant, percent time in open quadrants, open quadrant entries, and activity counts in
closed quadrants for the dams are presented in Table 4. No significant effects of exposure
were found on any of the dependent variables analyzed for the EZM.
Open field test. The effects of DES exposure on the percent time in the center,
number of center entries, percent time freezing, and percent time rearing for the dams are
presented in Table 5. No significant effects of exposure were found on any of the
dependent variables analyzed for the OFT.
Depression measures.
Tail suspension test. The effects of DES exposure on immobility time for the
dams are presented in Table 6. No exposure-related effects were found in the analysis for
immobility time in the TST.
Forced swim test. The effects of DES exposure on immobility time, basic
movements/struggle, and swim distance for the dams are presented in Table 7. No
significant effects of exposure were found on any of the dependent variables analyzed for
the FST.
Female offspring.
Anxiety measures.
Elevated zero maze. The effects of DES exposure and surgical status on the
latency to enter the open quadrant, percent time in open quadrants, open quadrant entries,
and activity counts in closed quadrants are presented in Table 8. Only one significant
exposure-related effect was found in the analyses for the EZM. For the variable of entries
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Table 4. Elevated Zero Maze Results Following Gestational DES Exposure in Dams
DES Dose
GD 11 - 17

Latency to
Enter Open
Quadrant
(Seconds)

Percent Time
in Open
Quadrants

0 µg/kg/day (n=9)

11.30 ± 4.73

13.38 ± 3.59

54.56 ± 17.17

1.60 ± 0.12

0.1 µg/kg/day (n=11)

5.62 ± 1.58

11.68 ± 1.98

59.55 ± 11.06

1.59 ± 0.09

1.0 µg/kg/day (n=8)

4.51 ± 1.92

15.14 ± 2.52

79.50 ± 10.92

1.89 ± 0.16

10.0 µg/kg/day (n=10)

4.55 ± 2.01

13.46 ± 4.00

60.20 ± 15.78

1.96 ± 0.22

Note. Means (± SEM); n = # of successful litters.
DES = Diethylstilbestrol
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Open
Quadrant
Entries

Closed
Quadrant
Activity
(Breaks/
Second)

Table 5. Open Field Test Results Following Gestational DES Exposure in Dams
DES Dose
GD 11 - 17

Percent Time
Center

0 µg/kg/day (n=9)

Number of
Center Entries

Percent Time
Freezing

Percent Time
Rearing

4.76 ± 1.32

17.33 ± 3.93

76.80 ± 2.15

9.11 ± 1.33

0.1 µg/kg/day (n=11)

6.62 ± 1.98

15.73 ± 2.89

79.50 ± 1.26

7.86 ± 0.73

1.0 µg/kg/day (n=8)

5.65 ± 1.79

18.13 ± 4.09

77.11 ± 1.78

10.85 ± 2.16

10.0 µg/kg/day (n=10)

5.33 ± 1.10

20.40 ± 4.27

74.98 ± 2.60

7.66 ± 0.74

Note. Means (± SEM); n = # of successful litters.
DES = Diethylstilbestrol
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Table 6. Tail Suspension Test Results Following Gestational DES Exposure in Dams
DES Dose
GD 11-17

Time Spent Immobile (Sec)

0 µg/kg/day (n=9)

258.89 ± 15.53

0.1 µg/kg/day (n=10)

230.91 ± 9.99

1.0 µg/kg/day (n=8)

226.80 ± 13.44

10.0 µg/kg/day (n=10)

229.28 ± 17.21

Note. Means (± SEM); n = # of successful litters.
DES = Diethylstilbestrol, Sec = seconds
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Table 7. Forced Swim Test Results Following Gestational DES Exposure in Dams
DES Dose
GD 11 - 17

Time
Immobile (sec)

Basic
Movements

Swim
Distance (cm)

0 µg/kg/day (n=9)

138.57 ± 10.16

934.33 ± 47.47

513.78 ± 23.71

0.1 µg/kg/day (n=11)

147.00 ± 6.97

921.36 ± 31.14

512.27 ± 14.75

1.0 µg/kg/day (n=8)

132.60 ± 8.58

977.88 ± 31.14

537.25 ± 15.05

10.0 µg/kg/day (n=10)

145.17 ± 8.32

936.70 ± 39.41

508.10 ± 20.57

Note. Means (± SEM); n = # of successful litters.
DES = Diethylstilbestrol; sec = seconds; cm = centimeters
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Table 8. Elevated Zero Maze Results Following Gestational DES Exposure in Female Mice
DES Dose
GD 11 - 17

Latency to
Enter Open
Quadrant
(Seconds)

Percent Time
in Open
Quadrants

Open
Quadrant
Entries

Closed
Quadrant
Activity
(Breaks/
Second)

0 µg/kg/day (n=9)
OVEX
SHAM
INTACT

3.09 ± 4.60
13.23 ± 3.47
2.48 ± 2.19

22.70 ± 4.60
17.12 ± 2.92
20.47 ± 3.79

76.67 ± 5.78
93.44 ± 14.42
91.22 ± 17.69

1.91 ± 0.14
2.24 ± 0.15
1.92 ± 0.23

0.1 µg/kg/day (n=12)
OVEX
SHAM
INTACT

11.21 ± 3.14
4.91 ± 3.01
10.33 ± 1.90

20.56 ± 3.77
20.43 ± 2.63
20.82 ± 3.53

102.50 ± 15.23
102.42 ± 8.66
80.83 ± 7.24

2.07 ± 0.12
2.10 ± 0.14
2.14 ± 0.17

1.0 µg/kg/day (n=7)
OVEX
SHAM
INTACT

3.54 ± 4.11
9.95 ± 3.94
1.45 ± 2.49

15.64 ± 4.73
21.52 ± 4.21
22.92 ± 5.24

80.86 ± 17.69
105.14 ± 12.67
75.00 ± 12.28

1.85 ± 0.19
2.21 ± 0.18
1.63 ± 0.24

5.89 ± 3.43
10.31 ± 3.30
5.30 ± 2.08

13.39 ± 3.35
18.22 ± 3.71
24.87 ± 3.79

82.50 ± 11.40
94.10 ± 8.43
101.70 ± 10.65

1.83 ± 0.08
1.95 ± 0.11
2.25 ± 0.09

10.0 µg/kg/day (n=10)
OVEX
SHAM
INTACT

Note. Means (± SEM); n = # of successful litters.
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into closed quadrants, there was a significant Exposure x Surgery x Quadrant interaction,
F(6,68) = 2.447, p = .033. Within each quadrant, further post hoc Dunnett tests revealed
that there were no significant exposure differences within any surgery group. Additional
post hoc simple contrasts found no significant surgery effects within any exposure group
(Figure 4).
While few DES exposure-related effects occured, several surgery-related effects
were found. A significant main effect of surgery was found for latency to enter an open
quadrant, F(2,33) = 3.334, p = .048. However, further post hoc simple contrasts revealed
no significant differences among the surgery groups (Figure 5). There was a significant
Surgery x Block interaction for entries into the open quadrants [F(8,27) = 2.646, p =
.028] and for entries into closed quadrants [F(8, 27) = 2.780, p = .022]. As can be seen in
Figure 6, in block 2, OVEX mice made significantly fewer entries into the open and
closed quadrants compared to the SHAM mice (p = .018 and .016, respectively). No other
surgery-related differences were found in any other block for either of these variables.
Open field test. The effects of DES exposure and surgical status on the percent
time in the center, number of center entries, percent time freezing, and percent time
rearing are presented in Table 9. No significant effects of exposure were found on any of
the dependent variables analyzed for the OFT, with the exception of percent time rearing,
for which there was a significant Exposure x Surgery x Block interaction, F(54,57) =
1.676, p = .028. Further post hoc analyses of the significant Exposure x Surgery x Block
interaction on percent time rearing revealed that in the OVEX group, the control group
spent significantly more time rearing compared to 0.1 DES group in both block 2 (p =
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Table 9. Open Field Test Results Following Gestational DES Exposure in Female Mice
DES Dose
GD 11 - 17

Percent Time
Center

0 µg/kg/day (n=9)
OVEX
SHAM
INTACT

11.66 ± 1.89
9.77 ± 1.64
20.79 ± 3.61

0.1 µg/kg/day (n=12)
OVEX
SHAM
INTACT
1.0 µg/kg/day (n=7)
OVEX
SHAM
INTACT

Number of
Center Entries

Percent Time
Freezing

Percent Time
Rearing

27.89 ± 3.90
28.11 ± 3.45
39.00 ± 5.38

71.13 ± 1.54
69.45 ± 1.94
66.21 ± 1.64

14.87 ± 1.16
12.37 ± 1.45
14.23 ± 2.00

10.37 ± 2.27
9.83 ± 1.72
16.41 ± 2.12

27.50 ± 2.66
26.67 ± 3.19
33.17 ± 3.13

69.82 ± 1.75
70.04 ± 1.55
66.15 ± 1.71

10.38 ± 0.65
10.67 ± 1.21
13.99 ± 1.23

9.24 ± 1.20
10.13 ± 2.33
12.00 ± 2.44

28.00 ± 2.10
30.57 ± 6.02
34.00 ± 5.50

70.56 ± 1.19
66.74 ± 2.26
69.15 ± 2.11

12.93 ± 1.19
11.39 ± 1.16
10.42 ± 1.91

10.0 µg/kg/day (n=10)
OVEX
11.22 ± 2.92
23.20 ± 4.00
72.18 ± 1.94
SHAM
12.54 ± 2.35
29.00 ± 3.97
70.07 ± 1.64
INTACT
13.27 ± 0.76
33.00 ± 2.71
67.40 ± 0.32
Note. Means (± SEM); n = # of successful litters.
DES = Diethylstilbestrol, OVEX = ovariectomy surgery, SHAM = sham surgery, INTACT = no surgery
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12.96 ± 1.36
15.10 ± 1.80
11.97 ± 0.97

Figure 4. Elevated Zero Maze: Entries into closed quadrants for female offspring.
Initial = Closed quadrant in which the mice were first placed. Opposite: Closed quadrant
on opposite side of maze.

59

Figure 5. Elevated Zero Maze: Latency to enter open quadrant for female offspring.
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Figure 6. Elevated Zero Maze: Entries into the open and closed quadrants for the female
offspring. A = OVEX group made significantly fewer entries compared to SHAM and
INTACT groups into the open and closed quadrants.
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.031) and in block 4 (p = .008), while there were no significant exposure effects in any of
the testing blocks within the SHAM or INTACT groups (Figure 7).
While few DES exposure-related effects were found, several surgery-related
effects were determined. A significant main effect of surgery was found for percent time
in the center [F(2, 33) = 6.589, p = .004], entries into the center [F(2,33) = 6.205, p =
.005], center activity counts [F(2,33) = 5.254, p = .010], peripheral activity counts
[F(2,33) = 6.395, p = .004], center vertical counts (rears) [F(2,33) = 5.813, p = .007], and
percent time frozen [F(2,33) = 7.726, p = .002]. Additional post hoc analyses revealed the
INTACT mice a) spent significantly more time in the center compared to the SHAM (p =
.001) and the OVEX (p = .004) mice (Figure 8), b) made more entries into the center area
compared to the SHAM (p = .007) and OVEX (p = .002) mice (Figure 9), c) had
significantly more activity counts (or photobeam breaks) in the center area than the
SHAM (p = .041) and OVEX (p = .001) mice (Figure 10), d) made significantly more
activity counts (or photobeam breaks) in the periphery than the OVEX (p < .001) mice
(Figure 11), e) made significantly more vertical counts in the center area compared to the
SHAM (p = .002) and OVEX (p = .002) mice (Figure 12), and f) spent significantly less
time frozen than the OVEX (p < .001) mice (Figure 13).
There was also a significant Surgery x Block interaction on the percent time spent
in the center, F(18,17) = 3.237, p = .010. As can be seen in Figure 8, in blocks 1, 8, 9,
and 10 INTACT mice spent more time in the center area than the OVEX mice (p = .012,
.005, .021, and .006, respectively). A significant difference was observed between the
INTACT and SHAM mice in blocks 1, 6, 8, and 9 (p = .037, .003, .047, and .001,
respectively).

62

Figure 7. Open Field Test: Percent time spent rearing for female offspring.
Top graph: OVEX group only; A = Control group spent significantly more time rearing
than the 0.1 DES group in these blocks. No other exposure effects were observed for this
variable.
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Figure 8. Open Field Test: Percent time spent in the center of the chamber for the female offspring. Below: INTACT group spent
significantly more time in center than the SHAM and OVEX groups. Inset: Percent time in center by block. A = INTACT group spent
more time in center compared to SHAM and OVEX groups during this block; B = INTACT group spent more time in center than the
SHAM groups in this block; C = INTACT group spent more time in center than the OVEX group in this block.
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Figure 9. Open Field Test: Entries into center of the chamber for the female offspring. INTACT group made significantly more
entries into the center than the SHAM and OVEX groups.
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Figure 10. Open Field Test: Activity counts (beam breaks) in the center of the chamber for the female offspring. The INTACT group
made significantly more activity counts compared to the SHAM and OVEX groups.
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Figure 11. Open Field Test: Activity counts (beam breaks) in the periphery of the chamber for the female offspring. The INTACT
group made significantly more activity counts than the OVEX group.
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Figure 12. Open Field Test: Vertical counts (rears) in the center of the chamber for female offspring. The INTACT group made
significantly more vertical counts in the center compared to the SHAM and OVEX groups.
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Figure 13. Open Field Test: Percent time spent frozen for the female offspring. The OVEX group spent significantly more time
frozen compared to the INTACT group.
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As indicated above, the three-way interaction of Exposure x Surgery x Block for
percent time rearing was also significant, F(54,57) = 1.676, p = .028. Within each block,
the effect of surgery within each level of exposure was also examined. For the 0 DES
group, the OVEX mice were significantly different from the SHAM mice (p = .015) in
block 2 while in block 4 the OVEX mice and INTACT mice spent significantly more
time rearing compared to the SHAM mice (p = .001 and .032, respectively). For the 0.1
DES group, INTACT mice spent more time rearing than the OVEX mice in blocks 6, 7,
8, and 10 ( p = .012, .025, .006, and p = .024, respectively). The INTACT mice also spent
more time rearing than the SHAM mice in blocks 6 and 10 (p = .003 and .018,
respectively). No significant Surgery differences were found in the 1.0 or 10.0 DES
groups (see Figure 7).
Depression measures.
Tail suspension test. The effects of DES exposure and surgical status on
immobility time are presented in Table 10. No exposure-related effects were found in the
analysis for immobility time in the TST. There was a significant Surgery x Block
interaction for time spent immobile, F(10,25) = 3.620, p = .004. Within-subjects simple
contrasts post hoc analysis within each block revealed significant surgery group
differences only within block 6. Specifically, the INTACT mice spent significantly more
time immobile compared to SHAM (p = .037) and OVEX (p = .014) mice (see Figure
14). No significant surgery differences were revealed in the other testing blocks.
Forced swim test. The effects of DES exposure and surgical status on immobility
time, basic movements/struggle, and swim distance are presented in Table 11. No
exposure-related effects on time spent immobile on the FST were found. However, for
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Table 10. Tail Suspension Test Results Following Gestational DES Exposure in
Female Mice
DES Dose
GD 11-17

Time Spent Immobile (Sec)

0 µg/kg/day (n=9)
OVEX
SHAM
INTACT

192.22 ± 16.16
199.90 ± 12.46
219.31 ± 11.37

0.1 µg/kg/day (n=12)
OVEX
SHAM
INTACT

193.53 ± 14.22
194.68 ± 13.19
206.22 ± 7.76

1.0 µg/kg/day (n=7)
OVEX
SHAM
INTACT

186.35 ± 13.88
191.31 ± 16.36
217.10 ± 13.54

10.0 µg/kg/day (n=10)
OVEX
SHAM
INTACT

191.95 ± 20.84
203.82 ± 7.61
198.06 ± 9.68

Note. Means (± SEM); n = # of successful litters.
DES = Diethylstilbestrol, OVEX = ovariectomy surgery, SHAM = sham surgery,
INTACT = no surgery, Sec = seconds
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Table 11. Forced Swim Test Results Following Gestational DES Exposure in Female Mice
DES Dose
GD 11 - 17

Time
Immobile (sec)

0 µg/kg/day (n=9)
OVEX
SHAM
INTACT

Basic
Movements

Swim
Distance (cm)

161.60 ± 13.56
189.92 ± 12.69
198.74 ± 10.59

829.11 ± 32.02
818.22 ± 65.08
826.00 ± 22.09

457.78 ± 30.08
406.44 ± 34.45
404.00 ± 19.04

0.1 µg/kg/day (n=12)
OVEX
SHAM
INTACT

164.70 ± 11.94
194.47 ± 7.08
177.89 ± 8.09

877.67 ± 34.98
861.25 ± 35.68
905.83 ± 36.00

481.25 ± 25.47
411.00 ± 15.47
433.88 ± 17.08

1.0 µg/kg/day (n=7)
OVEX
SHAM
INTACT

178.91 ± 6.66
191.05 ± 7.22
167.20 ± 12.12

814.57 ± 34.07
874.57 ± 54.07
911.29 ± 48.41

445.00 ± 20.90
421.00 ± 18.66
451.33 ± 19.37

10.0 µg/kg/day (n=10)
OVEX
177.24 ± 7.68
832.80 ± 23.36
447.40 ± 15.98
SHAM
189.68 ± 12.28
843.00 ± 35.89
403.63 ± 24.52
INTACT
181.71 ± 7.64
817.90 ± 35.45
407.86 ± 14.71
Note. Means (± SEM); n = # of successful litters; sec = seconds, cm = centimeters.
DES = Diethylstilbestrol, OVEX = ovariectomy surgery, SHAM = sham surgery, INTACT = no surgery
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Figure 14. Tail Suspension Test: Time immobile for female offspring. A = INTACT group spent significantly more time immobile
compared to the SHAM and OVEX groups in this block.
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basic movements/struggle there was a significant Exposure x Block interaction, F(15, 96)
= 1.878, p = .035, and a significant Exposure x Surgery x Block interaction, F(30,81) =
1.244, p = .011. The effect of exposure at each block and within each level of surgery
revealed that in the OVEX group, the 0 DES group made significantly fewer struggle
movements than the 0.1 DES group (p = .041) in block 2. In the INTACT mice, the 0
DES group made significantly fewer struggle movements compared to the 0.1 DES (p =
.038) and 1.0 DES (p = .009) mice in block 5. There were no significant exposure effects
in any blocks in the SHAM mice (see Figure 15).
For swim distance there was also a significant Exposure x Block interaction,
F(15, 96) = 2.096, p = .016, and a significant Exposure x Surgery x Block interaction,
F(30, 81) = 1.897, p = .012. Post hoc simple effects analyses (collapsed across surgery)
revealed no significant effects of exposure within any individual testing block.
Considering each surgical group separately, the effect of exposure at each block within
the INTACT group revealed the 0 DES group had a significantly shorter swim distance
compared to the 0.1 DES (p = .045), the 1.0 DES (p = .020), and the 10.0 DES (p = .044)
groups in block 4 and the 1.0 DES group (p = .010) in block 5. There were no significant
exposure effects in any blocks within the OVEX or SHAM groups (see Figure 16).
There was a significant main effect of surgery on time immobile, F(2, 33) =
4.535, p = .018, and swim distance, F(2,33) = 6.125, p = .005. The OVEX mice spent
significantly less time immobile compared to the SHAM mice (p = .002; Figure 17) and
had a greater swim distance compared to the SHAM (p < .001) and INTACT (p = .027)
mice (see Figure 18). There was also a significant Surgery x Block interaction on time
immobile, F(10,25) = 2.870, p = .016, and swim distance, F(10, 25) = 2.901, p = .015. As
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Figure 15. Forced Swim Test: Basic movements/struggle for female offspring.
Top graph: OVEX group only; A = Control group made significantly fewer basic
movements compared to the 0.1 DES group in this block. Bottom graph: INTACT group
only; B = Control group made significantly fewer basic movements compared to the 0.1
and 1.0 DES groups in this block. No exposure effects were observed in the SHAM
group.
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Figure 16. Forced Swim Test: Swim distance for female offspring (Exposure effect).
Bottom graph: INTACT group only; A = Control group had significantly shorter swim
distance than 0.1, 1.0, and 10.0 DES groups in this block; B = Control group had
significantly shorter swim distance than 1.0 DES group in this block. No exposure effects
were observed in the OVEX and SHAM groups.
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Figure 17. Forced Swim Test: Time immobile for female offspring. Below: SHAM group spent significantly more time immobile than
the OVEX group. Inset: A = SHAM group spent significantly more time immobile than the OVEX and INTACT groups in these
blocks.
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Figure 18. Forced Swim Test: Swim distance for female offspring (Surgery effect). Below: OVEX group had significantly greater
swim distance compared to the SHAM and INTACT groups. Inset: A = SHAM group had significantly shorter swim distance than
OVEX group in this block; B = SHAM group had significantly shorter swim distance than INTACT and OVEX groups in this block.
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can be seen in Figure 17 (inset), in blocks 3 and 4 (respectively) the SHAM mice spent
significantly more time immobile compared to the OVEX (p = .003, p = .002) and the
INTACT (p = .034, p = .003) mice. Likewise, in block 3, SHAM mice had a significantly
shorter swim distance than OVEX mice (p < .001), while in block 4, the SHAM mice had
a significantly shorter swim distance compared to the INTACT (p = .018) and OVEX (p
= .003) mice (see Figure 18 inset).
As previously mentioned, a significant Exposure x Surgery x Block interaction
was also found for basic movements, F(30, 81) = 1.897, p = .012 and swim distance,
F(30, 81) = 1.897, p = .012. For basic movements (see Figure 15), no significant surgery
differences were found within any blocks for the 0 dose DES group. For the 0.1 DES
group, it was revealed that in block 2, the OVEX mice made significantly more basic
movements compared to the SHAM mice (p = .008) while in block 4, the INTACT mice
made significantly more basic movements compared to the OVEX mice (p = .017). For
the 1.0 DES group, it was shown that in block 6, the INTACT mice made significantly
more basic movements than the OVEX mice (p = .005). Finally, for the 10.0 DES group,
the SHAM mice made significantly more basic movements compared to the INTACT
mice (p = .012) in block 6. For swim distance, no significant surgery differences were
found in any blocks for the control or 1.0 DES groups but this was not the case for the 0.1
and 10 DES groups (see Figure 16). For the 0.1 DES group, it was revealed that the
SHAM mice had a significantly shorter swim distance compared to the OVEX mice in
block 2 (p = .011) and block 4 (p = .011). For the 10.0 DES group, it was found that the
INTACT mice had significantly shorter swim distance compared to the SHAM (p = .043)
and OVEX mice (p = .013) in block 1, while in block 2 the SHAM mice had a
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significantly shorter swim distance compared to the INTACT (p = .003) and OVEX (p =
.022) mice.
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Chapter 5: Discussion
Summary of Results and Relation to Previous Literature
The overall results for this study revealed that exposure to varying doses of DES
during late pregnancy did not exert a robust, systematic influence over anxiety- and
depressive-like behaviors in C57Bl/6 dams or female offspring. Several effects of the
surgery manipulation were found in the female offspring, especially for anxiety-like
measures in the OFT and depressive-like measures on the FST. In general, on the OFT,
the INTACT group displayed less anxiety-like behaviors compared to the other surgery
groups, while on the FST, OVEX mice spent less time immobile and exhibited a greater
swim distance.
There were no significant exposure-related effects in any of the behavioral tests
for the dams. As previously stated, only a handful of experimental studies examining
DES exposure and its potential effects on tests of emotionality in rodents have been
published. There are no reports about the possible influence of adulthood DES exposure
on anxiety-like behavior; however, Estrada-Camarena et al. (2003) showed that a single
subcutaneous injection of DES in ovariectomized Wistar rats 48 hours before testing in
the FST did not elicit any significant behavioral alterations. Likewise, the present study
found no effects of DES exposure in ovariectomized mouse dams on any of the
behavioral measures, even after a more chronic schedule of exposure. These results imply
that DES exposure during late pregnancy does not impact the etiology of postpartum
depression or anxiety.
Concerning the female offspring in the current study, the only significant
exposure-related effect in the tests of anxiety was for percent time spent rearing in the
OFT, wherein the control OVEX mice spent more time rearing (an exploratory behavior)
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compared to the 0.1 DES OVEX mice in minutes 2 and 4 of the testing session. This
subtle DES-related finding was not robust enough to suggest that anxiety-like behavior
was significantly altered by exposure alone.
There have been inconsistent reports about the possible effects of developmental
exposure to DES on anxiety in rodents, and only two of these studies have included an
examination of the potential influence of DES in female offspring. For example, Kubo et
al. (2003) showed that intact male and female Wistar rats exposed to 6.5 µg/kg/day DES
from GD 0 to PND 21 via drinking water given to the dams resulted in an increase in
center time in the OFT, a decrease in anxiety-like behavior, on approximately PND 42. In
contrast, Tomihara et al. (2006) orally dosed C57Bl/6J mouse dams heterozygous for
ERαKO with 0.1 µg DES or control vehicle from GD 11 to 17. Behavioral testing
occurred around PND 35 in both ERαKO and wild type intact male and female offspring.
Regardless of genotype, DES-exposed males and females displayed more anxiogenic
behavior in the OFT compared to control animals. Tomihara et al. (2006) also showed
that wild type DES-exposed females were more anxious in the Light/Dark Chamber,
while the wild type DES-exposed males displayed anxiolytic behavior; those results were
consistent with other findings that have reported a reversal of sex differences following
developmental exposure to estrogenic compounds in tests of anxiety-like behavior in
rodents (Farabollini, Porrini, & Dessi-Fulgheri, 1999; Fujimoto, Kubo, & Aou, 2006;
Gioiosa et al., 2013; Kubo et al., 2001; Palanza et al., 2008).
There are some critical methodological aspects to consider when comparing the
present investigation with these two studies. The current study controlled for any type of
excess exposure to other estrogenic compounds during development (i.e., non-
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polycarbonate plastic cages, filtered water in glass water bottles, low-soy rodent chow).
Both the Kubo et al. (2003) and Tomihara et al. (2006) studies did not utilize such
controls. Other substantial differences between the current study and the report from
Kubo et al. (2003) are in regard to the rodent species used (Wistar rats versus C57Bl/6
mice) as well as the duration of DES exposure (GD 0 to PND 21 versus GD 11 to 17).
Further, mice in the Tomihara et al. (2006) study were tested during their dark cycle
while mice in the present study were tested during the light cycle. In addition, the current
study conducted behavioral testing in adult offspring to examine potential emotionrelated effects caused by developmental DES exposure that could persist later in life. In
contrast, both Kubo et al. (2003) and Tomihara et al. (2006) conducted behavioral tests in
intact animals that had not yet reached adulthood (PND 42 and PND 35, respectively),
and unexposed adolescent rodents have been shown to perform differently from their
adult counterparts on tests of emotionality (Adriani & Laviola, 2004). For example, it has
been shown that C57Bl/6J mice in periadolescence displayed more anxiety-like behavior
in the OFT compared to adults (Hefner & Holmes, 2007).
With regard to alterations in depressive-like behaviors following developmental
exposure to DES, there are no published reports. In the present study, no exposure-related
effects were found for time spent immobile in either the TST or FST, the primary
measure of behavioral despair in these assays. However, there were significant DES
effects for both basic movements/struggle and swim distance in the FST. In the OVEX
group, control mice struggled less than the 0.1 DES mice in minute 2 of the test. Also, it
was shown that within the INTACT mice, controls made fewer struggle movements
compared to the 0.1 and 1.0 DES groups in block 5 only. Both of these results show that
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for both the OVEX (i.e., no circulating E2) and the INTACT (i.e., circulating E2) groups,
control mice with no DES exposure actually displayed more behavioral despair in these
select testing blocks. For swim distance, it was shown that INTACT controls swam less
than all DES groups in block 4 and that the controls also had significantly shorter swim
distance than the 0.1 DES group in block 5 of the testing session, suggesting that the
INTACT control mice displayed more behavioral despair compared to the INTACT
DES-exposed mice in these specific blocks of time. These findings, however, did not
illustrate a strong, systematic effect of DES exposure, suggesting that early
developmental exposure to this potent estrogenic compound does not lead to significant
alterations in depressive-like behavior in either of these tests of behavioral despair during
adulthood.
Many epidemiological studies examining the incidence of emotion-related
disorders in the human population that was exposed to DES in utero have been published.
While several of these investigations have reported significant differences in
psychological problems, specifically increased rates of anxiety and depression-related
disorders (Meyer-Bahlburg et al., 1985; O’Reilly et al., 2010; Pillard et al., 1993; Vessey
et al., 1983), others have reported no such discrepancies between DES-exposed women
and control groups (Ehrhardt et al., 1987; Fried-Cassorla et al., 1987; Titus-Ernstoff et
al., 2003; Verdoux et al., 2007). In the careful consideration of these epidemiological
studies, one critical and very possible confound has been present - was the increased
incidence of psychological disorders in DES-exposed women due to this estrogenic
compound altering development and organization of the brain and central nervous
system, or was it due to other environmental factors (i.e., knowledge of increased risk of
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cancer, stress and concern regarding other aspects of gynecological health such as
abnormal reproductive organs and infertility) (Fried-Cassorla et al., 1987; Kebir & Krebs,
2012)?
To attempt to control for this confound, two studies have employed clinical
control groups in their analysis of rates of psychiatric disorders and symptoms. For
example, Ehrhardt et al. (1987) included a clinical control group that consisted of women
with abnormal Papanicolaou smears (abnormal PAP group) in the same age range and of
similar socioeconomic status compared to the DES-exposed group. The authors
suggested that the inclusion of this particular clinical control group was appropriate,
because both the DES-exposed women and the abnormal PAP women would have
undergone similar medical procedures in addition to having higher risk of reproductive
health problems and increased rates of genital cancer. To summarize, Ehrhardt et al.
(1987) reported that the DES-exposed women and the abnormal PAP women had
significantly increased rates for anxiety and depression symptomatology on the SCL-90R (a self-report assessment) in comparison to population norms, but the two groups did
not significantly differ from each other. Likewise, Fried-Cassorla et al. (1987) also
included an abnormal PAP clinical control group in addition to a control group that
consisted of unexposed sisters of women in the DES group. Using the DIS/DSM III (a
highly structured interview to assess psychiatric illness diagnoses), these authors reported
that both the DES-exposed women and the abnormal PAP women had significantly
increased incidence of major depression compared to the unexposed sister controls;
however the DES group and the abnormal PAP group were not different from each other
in the rate of this diagnosis (Fried-Cassorla et al., 1987).
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A more recent epidemiological study using a large cohort (from the National
Cancer Institute) asked DES-exposed women about issues with psychiatric illness using a
self-report questionnaire; no differences in the frequency of depression, anxiety,
psychosis, or eating disorders between the DES cohort and unexposed sisters and agematched controls were found (Titus-Ernstoff et al., 2003). Furthermore, Verdoux et al.
(2007) surveyed mothers (all participating in a French general population survey) using
self-report questionnaires. The mothers provided information on psychiatric outcomes for
DES-exposed children as well as unexposed siblings, and results revealed that there were
no differences between the groups.
In agreement with the current study’s experimental results, these epidemiological
findings suggest that it was not DES exposure alone that resulted in increased rates of
psychiatric illness including anxiety and depression disorders. However, it is more likely
that the elevated risk of developing such symptomatology is associated with patients’
current environmental stressors, such as concern over reproductive health problems,
increased risk of cancer, and significant problems with infertility.
While few effects of DES exposure were found, the surgical manipulation did
reveal some differences. On the EZM, it was shown that the OVEX mice made
significantly fewer entries into both the open and closed quadrants compared to the
SHAM mice but this was in block 2 only, suggesting that the OVEX mice displayed more
anxiety-like behavior and were less active than the SHAM mice during this specific time.
In the OFT, more robust effects of the surgery manipulation were revealed. INTACT
mice spent significantly more time in the center compared to the SHAM and the OVEX
mice, made more entries into the center area compared to the SHAM and OVEX mice,
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had significantly more activity counts in the center area than the SHAM and OVEX mice,
made significantly more photobeam breaks in the periphery than the OVEX mice, reared
significantly more in the center area compared to the SHAM and OVEX mice, and spent
significantly less time frozen than the OVEX mice. All of these results imply that the
INTACT mice displayed an overall decreased level of anxiety-like behavior compared to
both the OVEX and SHAM groups. While these differences between the INTACT and
OVEX groups were predicted, the disparities between the INTACT and SHAM groups
were not expected and have been attributed to differences in circulating E2 that were not
controlled (i.e., estrous cycles of mice were not tracked).
Numerous reports concerning the influence of differing E2 levels (whether due to
naturally circulating levels or administration of E2) on anxiety and depressive-like
behaviors in rodents and symptoms in humans have been published. For example,
Marcondes et al. (2001) has shown that rats in the proestrus phase of the cycle (i.e., high
circulating levels of E2) spent more time in the open arms of the Elevated Plus Maze
compared to rats in the diestrus phase (i.e., low circulating levels of E2). In addition,
direct E2 administration to the amygdala in OVEX’d rats has been reported to induce
anxiolytic behavior in the OFT and EPM (Frye & Walf, 2004a). Reports of clinical trials
regarding treatment with hormone replacement in peri-menopausal women, young
women with naturally low levels of E2, and women suffering from postpartum
depression given E2 therapy have reported overall improved mood (Cohen et al., 2003;
Smith, Studd, Zamblera, & Holland, 1995). Such results support the current study’s
findings that INTACT mice displayed less anxiety-like behaviors in the OFT compared to
the OVEX mice. However, these significant effects of surgery cannot be completely

87

attributed to the activity of estrogen alone. Other factors, such as the other hormone (i.e.,
progesterone) and neurotransmitter (i.e., serotonergic, GABAergic) systems that interact
with E2 and also affect behavior could be at play. Further, the differences that were
observed between the INTACT and SHAM mice could also be illustrating how powerful
the effects of a surgical procedure can really be (i.e., anesthesia effects, stress of followup injections and the recovery process).
With regard to surgery-related effects in the tests of depressive-like behaviors, the
current study showed that INTACT mice spent more time immobile compared to both the
OVEX and SHAM mice but only during the last minute of testing in the TST. However,
as seen in Figure 14, the mean difference in this final minute of the entire testing session
was only 4 to 5 seconds; thus, it seems reasonable to conclude that no real differences in
depressive-like behavior were observed in the TST. In the FST, OVEX mice spent less
time immobile than the SHAM mice and had a greater swim distance compared to both
the SHAM and INTACT mice. These results indicate that the OVEX mice displayed less
depressive-like behavior compared to the groups with circulating E2.
Others have reported effects of E2 administration in adult rodents and subsequent
alterations in depressive-like behavior. For example, Rachman et al. (1998) reported that
seven daily subcutaneous injections of estradiol benzoate in OVEX’d Sprague-Dawley
rats resulted in a decrease in immobility compared to controls in the FST. Similarly,
Estrada-Camarena et al. (2003) showed that OVEX’d Wistar rats given a subcutaneous
injection of E2 also had a decrease in immobility time compared to control rats in the
FST. There are few published reports concerning circulating E2’s influence on
depressive-like behaviors in adult rodents. However, Vega-Rivera, Fernandez-Guasti,
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Ramirez-Rodriguez, and Estrada-Camarena (2013) have shown that rats in proestrus
displayed less immobility time in the FST compared to OVEX’d rats. It is important to
note, though, that all of these investigations have used rats, while the present study
utilized mice.
Future Research
Because DES is such a potent estrogenic EDC that has been shown to affect
various outcomes in brain tissue (i.e., size of sexually dimorphic regions) (Kubo et al.,
2003), it is still plausible that under the right circumstances, emotion-related behaviors
could be perturbed by exposure, particularly during early development. Epigenetic
research has associated EDCs and DNA methylation in the etiology of psychiatric illness
(Abdolmaleky et al., 2004). It has been shown that early developmental exposure to DES,
BPA, and other estrogenic compounds elicited altered methylation patterns in CpG
islands in promoter genes, leading to modified gene expression in specific tissues (Li,
Hursting, Davis, McLachlan, & Barrett, 2003). For instance, E2 has been found to reduce
transcription of catechol-O-methyl transferase (COMT), one of many genes implicated in
bipolar disorder and schizophrenia when hypomethylation occurs in its promoter region
(Abdolmaleky et al., 2006; Jiang, Xie, Ramsden, & Ho, 2003). It has also been
speculated that polymorphisms in genes that modulate epigenetic machinery and that are
thought to promote genetic susceptibility for bipolar disorder and unipolar depressive
disorder (i.e., the common MTHFR C677T polymorphism; MTHFR is also a crucial
enzyme that controls one-carbon metabolism and regulates methyl donors, a primary
epigenetic mechanism) in addition to DES exposure in utero could exacerbate the risk of
developing such psychiatric illness (Krebs, Bellon, Mainguy, Jay, & Frieling, 2009;
Peerbooms et al., 2011). Therefore, future research should further examine potential DES
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effects on the epigenetic level and how such alterations may impact psychiatric outcomes
including emotion-related behaviors.
Another consideration for future research in this area is in regard to examination
of male offspring behavior. Though not as much has been reported concerning DES sons’
incidence of anxiety and depression disorders, it is still an important outcome to consider,
especially because it has been shown that developmental exposure to other estrogenic
compounds has resulted in a feminization of male emotion-related behaviors in rodents
(Farabollini et al., 1999; Fujimoto et al., 2006).
In addition, previous work with DES has found that administration of this potent
estrogen during early development has elicited alterations in sexually dimorphic nuclei of
the brain. For example, Kubo et al. (2003) reported that early DES exposure in rats
increased volume of the locus coeruleus (LC) in males and decreased LC size in females,
thereby reversing the sex difference observed in control animals. Brain samples from the
current study were collected and appropriately stored for later analyses. Thus, future
assays of potential alterations of receptor expression and/or examination of changes in
sexually dimorphic brain regions should be conducted.
Finally, to obtain a more complete appreciation of the potential influence of
exposure to estrogenic EDCs, future research should follow the suggested
methodological criteria put forth by the US Food and Drug Administration (FDA) for
BPA studies. Even though those standards were recommended specifically for BPA, they
are also useful for research on other estrogenic EDCs. Because contact with most EDCs
occurs through ingestion of contaminated food and water, oral administration is the
preferred route. In order to detect a potential dose-response, it was recommended that at
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least three relevant dose levels (not including control), ranging from a higher dose to a
very low dose, should be employed. Further, additional sources of environmental
estrogens should be controlled by using low phytoestrogen diets and utilizing glass water
bottles and non-polycarbonate cages (U.S. Food and Drug Administration [U.S. FDA],
2009).
Limitations
The primary limitation in the current study was the lack of control for cycling E2
in the SHAM and INTACT mice. Because their cycles were not tracked, these groups
may have been in various stages of the estrous cycle, leading to increased variation in
their performance on the behavioral tasks used, though it is presumed that other factors
such as the stress and recovery from the surgical procedure itself may have impacted
these results. However, there were still significant effects of surgery where the OVEX
group displayed more anxiety-like behavior in the OFT, particularly in comparison with
the INTACT group, and decreased depressive-like behavior on the FST.
Another shortcoming in this study was the large expanse of time between DES
exposure in the dams and behavioral testing. Others have shown that depressive-like
behaviors have been increased in rodents soon after parturition (Molina-Hernandez &
Tellez-Alcantara, 2001). Because all the dams were ovariectomized, behavioral testing
soon after exposure was not possible, as they needed a sufficient amount of time to fully
recover from surgery as well as to allow circulating E2 to be reduced. However, the
purpose of the current study in investigating possible behavioral changes in the dams was
to see if DES exposure during pregnancy, a time of radical neurosteroid oscillation, could
influence persistent postpartum emotion-related consequences. The results demonstrated
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that administration of DES during this time did not elicit any significant behavioral
changes in the dams.
Conclusions
DES is not a safe compound, and exposure to this teratogen should be avoided as
it has been shown to cause extremely detrimental effects, particularly in reproductive
tissues and organs. In addition to such negative physical consequences, there have been
many reports concerning developmental exposure to DES and its effect on alterations in
emotion-related behaviors in lab animals as well as increases in rates of psychiatric
illness in people that were exposed in utero, particularly DES daughters. However, this
study has provided results suggesting that exposure to DES during late pregnancy did not
alter emotion-related behaviors in either dams or female offspring. The lack of any
meaningful DES-related effects on all tests of emotionality implied that the augmented
level of anxiety and depression disorders documented in previous epidemiological reports
is more likely due to current environmental factors regarding significant distress and
concern about impending or existing health problems as opposed to DES exposure
influencing brain organization and development. The current study did find several
effects of the surgical manipulation that suggested OVEX mice displayed more anxietylike behavior in the OFT compared to mice with naturally circulating levels of E2. Such
results suggested that alterations in E2 (in addition to other potential effects of the
surgical procedure alone and/or changes in other hormone levels and neurotransmitter
systems that can interact with E2) can elicit changes in emotionality.
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